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EFFECTS OF ANTI-Aß MONOCLONAL ANTIBODIES ON THE AMYLOID
BETA PEPTIDE FIBRILLOGENESIS AND THEIR INVOLVEMENT IN THE
CLEARANCE OF ALZHEIMER’S DISEASE PLAQUES
Jeffy Pilar Jiménez
ABSTRACT
Alzheimer’s disease (AD) is the most common cause of senile dementia
worldwide. AD is a neurodegenerative disorder characterized by the loss of
memory and language skill, collapse of the cognitive function, and distortion of
social behavior. As of today, the onset mechanisms of AD and cure are
unknown; however, three hallmarks are commonly encountered: extra and
intracellular accumulation of amyloid beta (A!) peptide plaques, formation of
intracellular neurofibrillary tangles, and inevitable neuronal death. Hypothetically,
a possible scenario provoking or involved in the onset of AD is a cascade effect
that starts with an imbalance in the production and clearance of Aß peptide that
consequently leads to its accumulation, formation of tau protein tangles and
neuronal death. This work studied and characterized the mechanisms governing
A! peptide aggregation and the effects of using anti-Aß monoclonal antibodies to
modify this process. These mechanisms play an important role in the formation
xiii

of AD plaques and are critical in the search for therapies involving Aß peptide
plaque clearance. Yet, antibody-based therapies for plaque clearance are not
well understood, adding to the existing concerns about side effects in humans,
hence there is a necessity of knowledge in this matter. In this work different Nterminus, C-terminus, and Mid-domain antibodies were used against Aß peptide
species (monomers, oligomers, and fibrils) to probe peptide aggregates
modification and disruption. Additionally, construction of a soft supported lipid
bilayer membrane was proposed to study the adhesion mechanisms of Aß
peptide and interactions with antibodies, mimicking the neuronal cell surface. The
main characterization techniques used in this work were: atomic force
microscopy (AFM) and transmission electron microscopy that allowed the
physical exploration and visualization of the different processes of aggregation in
terms of adhesion, size evolution, and distribution of the peptide; and attenuated
total reflectance Fourier spectroscopy (ATR/FTIR) which allowed monitoring the
change of secondary structures for the peptide during the processes studied. It is
endeavored that this work will help to elucidate the effects attributed to the
molecular interactions between A! peptide species and antibodies to target Aß
plaque’s clearance in the brain of AD patients. Ultimately, this study provides
novel information critical for the formulation of effective therapies to prevent and
treat AD with less collateral effects. It also represents a contribution to the basic
scientific knowledge regarding peptide-antibody interactions with application to
other diseases related to protein misfolding.
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CHAPTER 1
INTRODUCTION AND PREMISES

1.1.

Alzheimer’s Disease Facts and Current Therapeutics
Alzheimer is an irreversible neurodegenerative disease characterized by

the progressive loss of memory, coordination, social skills, and reasoning. In
2006 Alzheimer’s disease (AD) was reported as the sixth leading cause of death
across all ages in the United States [1, 2]. Furthermore, AD significantly reduces
the life expectancy and quality of those afflicted by it [3]. Statistics show that
before a person’s 65th birthday 1 person in every 1000 is diagnosed with AD, and
after this age this rate increases to 1 person in every 8. The chance raises to 1
person in every 5 after the age of 80 [4].
As of today, nearly five million Americans live with AD [5]. This number is
expected to quadruple in the next four decades [5]. Worldwide AD cases have
reached 26 million people, and it is expected to increase to 106 million by 2050.
In addition, reports show that in the United States alone the government and
affected families spend approximately 148 billion dollars annually to treat patients
with AD [1, 5].
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The onset mechanisms of AD and the cure are still unknown; however,
three pathological hallmarks are commonly observed among patients with AD:
the presence of extracellular deposits of amyloid beta (Aß) plaques, intracellular
neurofibrillary tangles (NFTs), and neuronal apoptosis. Figure 1 (a) and (b)
shows the first two major microscopic hallmarks mentioned above [6].
In this work special attention is rendered to understanding the process of
Aß plaque formation and clearance.
Aß peptide deposits (also known as senile plaques) are mainly composed
of amyloid beta peptides containing 1-40 and 1-42 amino acids residues (Aß1-40
and Aß1-42 respectively) [7-9].

Figure 1. Alzheimer’s Disease Hallmarks. (a) Left: a normal neuron. Right:
depicting the three hallmarks of AD (Aß plaques, NTF’s, and neuron’s
apoptosis) [10]. (b) Classical histopathology of AD’s brain showing plaques
and neurofibrillary tangles (arrows), taken from Cordell, 1994 [11]
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Despite the fact that Aß peptide does not have a known function in the
brain, it is present in healthy brains. Studies show that insoluble Aß peptides
along with a soluble sub-product are proteolytically cleaved from a larger
transmembrane protein known as amyloid precursor protein (APP) [12, 13].
Soluble forms of APP are believed to have neuroprotective and
neurotrophic functions. However, A! is considered an unwanted by-product of
the APP processing [4]. The A! peptides are found as globular and non-fibrillar
forms in small concentrations of pico- to nano-molar and can be traced in the
extracellular and cytoplasmic (inside the cell) regions in both normal and AD
brain tissues. Nevertheless, significantly small oligomeric and protofibril species
of A! peptides are enough to cause profound cytoskeletal degeneration and cell
death by plaque formation through underlying mechanisms still not understood
[14-20].
It is also known that plaques and tangles are accumulated in neurons,
mainly throughout the cortical and limbic brain regions [21]. The cortical region is
responsible for the abilities and activities related to thinking, basic aspects of
perception, movement, and adaptive response to the outside world. The limbic
region is primarily responsible for emotional behavior and the formation of
memories [22].
In the past decade there have been significant advances in the field of AD;
however, an effective treatment for its cure is not available yet [23]. Currently,
some common drugs containing active ingredients such as cholinesterase
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inhibitors1 or glutamine regulators2 are not able to cure the disease. Rather,
these drugs only serve to “delay the progression of some of AD’s symptoms”
[24].
There is a tremendous need to find an effective treatment that radically
stops and prevents the brain’s cognitive degeneration and the irreversible loss of
memory. A feasible and promising treatment is immunotherapy. In the past,
active immunization (vaccination) was tested in a phase II clinical trial [25, 26],
which was suspended after observing severe undesired immune response to the
treatment (7% of the patients out of 312 subjects presented encephalitis).
Nevertheless, patients monitored afterward showed less cognitive function
degeneration in comparison to the control individuals, and this study gave
important insights into immunotherapeutic treatments [26, 27].

1

Razadyne® (galantamine) also known as Reminyl®, Aricept® (donepezil), Cognex®

(tacrine, with safety concerns), and Exelon® (rivastigmine); these are usually prescribed
to patients with mild to moderate AD, to prevent the cholinesterase’s breakdown.

2

Namenda® (memantine), an N-methyl D-aspartate (NMDA) antagonist; prescribe to

patients with moderate to severe AD, to regulate production of glutamate (in large
amounts leads to brain cell death).
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A possible therapy currently under study is passive immunization, which
consists of the administration of monoclonal antibodies as a means to assist the
dissolution and clearance of A! peptide plaques from the brain in patients with
AD.

1.2.

Hypothesis
It is possible to assess the effects of different monoclonal anti-Aß

antibodies directed against aggregates of Aß peptides in vitro.

1.3.

Specific Aims and Objectives
With the purpose of proving the current hypothesis, the work was divided

into four specific aims, explained below.

1.3.1. In vitro Assessment of Physicochemical Changes Endured by A!Peptide during Aggregation
The aggregation process of Aß peptides was first monitored and
characterized chemically by attenuated total reflection Fourier transform infrared
spectroscopy (ATR-FTIR); this technique allowed the identification of the
peptide’s secondary structures involved in such event. The chemical
characterization results were then checked by the physical characterization of the
species encountered at different collection times using atomic force microscopy
(AFM).
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Two isoforms of Aß peptide, Aß1-40 (with 40 amino acid sequences) and
Aß1-42 (with 42 amino acid sequences), were studied individually and in
combination (1:1 Aß1-40 to Aß1-42 equimolar mixture, Aß40/42). The main objective
was to create a baseline understanding of the kinetic and structural processes
during fibrillation and to adapt an analytical method for posterior studies.

1.3.2. Analysis and Evaluation of Effects of Monoclonal Antibodies on Aß
Peptide Fibrils
The purpose was to determine the effects of antibodies on mature fibrils.
The antibodies used for this study had different affinity and specificity. The
substoichiometric molar ratio of antibody to peptide used in this study was
1:1000.

1.3.3. Influence of Monoclonal Antibody on the Initial Phase of Fibrillization
Physical, chemical, and biochemical methods were used to analyze the
action of different antibodies on Aß peptide species. This aim focused on
understanding the extent to which the antibodies were influencing the
aggregation process and to evaluate the possible effects on plaque clearance, by
targeting monomers + oligomers, being this the initial phase of aggregation.

6

1.3.4. Construction and Evaluation of a Biomimetic Cell Membrane as a
Soft Substrate for Future Studies Involving Peptide-Antibody Interactions
The main objective was to produce a stable, soft support that could serve
to mimic the role played by the cell membrane as a substrate for the AD plaques
and to test the action of monoclonal antibodies on Aß peptide aggregates.

1.4.

Contribution of this Work
The principal contribution of this work was to provide an in vitro method to

evaluate the effects of antibodies on amyloid beta peptide species, probing their
effectiveness to destabilize neurotoxic forms of Aß and disrupt their natural
aggregation pathway.
This work provided basic scientific knowledge to help understand and
improve antibody-based therapies for AD, with extension to other protein
misfolding related diseases.

1.5.

Broader Impacts
The methods and findings from this work opened paths to evaluate critical

biomolecular interactions to understand protein misfolding related diseases and
possible therapies.

7

CHAPTER 2
BACKGROUND

This chapter gives a general review of concepts and principles that
provide the bases to later discuss our results and explain the phenomena
observed during the different studies performed in this work.

2.1.

Amyloid Beta Peptide, Aggregation Process, and Plaque Formation
The name amyloid comes from the Latin “amylum” and Greek “amylon”,

meaning starch in both languages. Rudolf Virchow in 1854 used this name to
refer to the material deposited in the brain as macroscopic abnormalities, due to
its reactivity to iodine-sulfuric acid, a reagent used to identify starch and cellulose
derivatives [28]. It was later in 1859 when Friedreich and Kekule demonstrated
that the material identified as cellulose was protein [29].
Amyloid peptides are not exclusive to Alzheimer’s disease (AD). They are
also associated with diseases in other organs such as the liver, spleen, and
kidney [29]. The amyloid peptide found in neuritic plaques in AD patients is
known as amyloid beta (A!) peptide due to its natural tendency to form !-sheet
secondary structures [30].
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As mentioned in Chapter 1, AD’s neuritic plaques are mainly composed of
two isoforms of A! peptide, A!1-40 and A!1-42 [31]. These peptides are fragments
produced by the proteolytic cleavage of a larger transmembrane molecule (APP),
a process briefly sketched in Figure 2. The products of this proteolytic cleavage
are soluble neuroprotective secreted ectodomain sAPP" (via "- secretase
cleavage) and extracellular A!40/42 peptides (via consequent ! and #-secretase
cleavage) [32, 33]. It is worth mentioning that even though the concentration of
secreted Aß1-42 is near 10% of the Aß1-40 concentration, Aß1-42 peptide is the
main component of neuritic plaques deposits [13, 34].

Figure 2. Amyloid Beta Peptide Enzymatic Cleavage. Schematic of Aß1-40 and
Aß1-42 production by cleavage of the APP proteins by the intervention of
specialized enzymes
9

The mechanisms of neuritic plaque formation are still unclear. However, it
has been suggested that soluble species of A! peptide undergo a series of
molecular rearrangements (misfolding) triggered by environmental stress that
lead to the formation of fibrillar deposits.
Under normal conditions, cells with elaborate quality control machinery
guarantee that proteins folded improperly are eliminated. This machinery
includes proteins, specialized organelles and cells that act as chaperones and
activate processes to selectively eradicate misfolded proteins. In the case of the
central nervous system (CNS) the specialized quality control cells are the
microglial cells. Proteasomes and lysosomes structures also contribute to the
degradation and elimination of misfolded proteins inside cells [35].
However, a particular characteristic that distinguishes amyloid and a few
other misfolded proteins (such as alpha synuclein, cystatin c and tau among
others) is the ability to aggregate into higher order species such as oligomers,
protofibrils, and fibrils. These species cannot be transported into the central
catalytic pore of the proteasome enzyme complex for degradation. This
characteristic allows amyloid peptides to evade proteasome and lysosome
quality control machineries, which leads to accumulation of misfolded
amyloidogenic peptide. This system grows and propagates, offering resistance
to degradation for the amyloid toxic [6]. In addition, a small increase in the
concentration of misfolded protein can dramatically accelerate the process of
plaque formation [36].
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In vitro amyloid beta peptide fibrillization can be recreated and studied at
different levels of aggregation by manipulating the peptide’s concentration,
temperature, pH, and ionic strength of the media [37, 38]. Similarly, it is possible
to alter and destabilize production of Aß species (oligomers, and protofibrils)
critical during fibrillogenesis by introducing an external agent (i.e. beta sheet
breakers). Although active and passive immunotherapy have shed light into the
possible mechanism involved in the activation of the immune system and
clearance of Aß from the brain, little is known about the impact on protein folding
produced by monoclonal antibodies binding to Aß peptide. This work evaluates
the anti-Aß monoclonal antibodies molecules as external agents used to alter
peptide’s aggregation and promote peptide solubility.

2.2.

Amino Acids, Peptide Bond, Peptides, and Levels of Structure
Amino acids are the building blocks of peptides and polypeptides. They

are formed by two main functional groups: an amino and a carboxyl group, which
are both linked through a chiral central carbon atom (C") that also holds
hydrogen bonding and a distinctive R group (side chain) as shown in Figure 3.
The arrangement of these constituents around the central carbon atom makes
them chiral, meaning they have two isomers, L-isomer and D-isomer. However,
the L-isomer is found only in peptides and polypeptides. Naturally, the amino
acid residues present in a peptide or polypeptide molecule influence the
properties and adopted conformations.
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Figure 3. General Amino Acid’s Structure

Peptides and polypeptides are sequential and unbranched polymers of
amino acids linked from head to tail, with less than 50 and more than 50 amino
acid residues, respectively [39].
The union between a carboxyl group and an amino group through a
covalent amide linkage is referred to as a peptide bond [35], which is shown in
Figure 4. The peptide bond is essentially planar, and it has what is considered a
double-bond strength that prevents free rotation around it. However, vibration
and translation are possible. In this study, though, only vibration was quantifiable
with ATR-FTIR spectroscopy; as it will be explained in Chapter 3.
It is important to mention that the peptide bond is uncharged, and this
absence of charge allows the amino acid chains to tightly pack together, linked
by peptide bonds into globular structures [39]. The main event responsible for
the change in conformation will be the loss or gain of protons depending on the
media’s pH. The molecular interactions among peptides are also affected by
temperature changes and the media’s ionic strength.
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Figure 4. Amino Acids to Peptide and the Peptide Bond

A final point pertinent to this section is the presentation of the four different
levels of structure adopted by peptides and polypeptides, which are explained as
follows.

2.2.1. Primary Structure
They are simply formed by an amino acid sequence in a linear fashion and
without taking into account three-dimensional rearrangements of the residues.

2.2.2. Secondary Structure
They represent a three-dimensional arrangement of the polypeptide in the
space. This is conceived by the disposition of the hydrogen bonds between
13

adjacent amino acid residues in a molecule and between molecules, which
allows the peptide molecules to arrange themselves into characteristic patterns.
The following were the main secondary structures or patterns investigated in this
work: parallel ß-sheet, antiparallel ß-sheet, "-helix, unordered (or random coils),
and ß-turns structures, shown as part of the short peptide in Figure 5.

Figure 5. Peptide’s Secondary Structures

The most important and known secondary structures are the helical and
pleated segments (formed by parallel or antiparallel ß-strands). These segments
constitute regular structures that extend along one dimension. Most proteins
exhibit these types of structures, which allow peptides to play specific roles in the
body.
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2.2.3. Tertiary Structure
This structure is present when polypeptide chains assume a tight threedimensional shape, adopting a globular form. This type of structure gives to the
polypeptides a lower surface-to-volume ratio allowing the molecules to shield
from the solvent [35].

2.2.4. Quaternary Structure
This structure is composed of several folded peptides or polypeptides that
are gathered in a more complex molecule, as in the case of enzymes.

2.3.

Antibodies
Antibodies, also known as immunoglobulins, are natural bioengineered

proteins with high binding specificity to a wide range of molecules including
peptides, carbohydrates, and nucleic acids [40]. Figure 6 shows the
characteristic parts of an antibody molecule. Antibodies have a particular “Y”
shape, which is formed by two heavy chains and two light chains. The type of
heavy chain determines the antibody isotype (Figure 7) to which they belong.
The Fab (fragment antigen binding) region of the antibody is composed of
domains from both heavy and light chains of the antibody, and plays an important
role in the binding and specificity to a particular site of the antigen known as the
epitope. In the case of this work, the antibodies used were specific to Aß
peptides, either 1-40, 1-42 or both, with epitopes variable depending on the
antibody.
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Figure 6. Sketch of an IgG Monoclonal Antibody Molecule. The region of light
chains is generally recognized as Fab and promotes specific biding
characteristics

The distinction between the different antibody isotypes is based on their
heavy chain, which in turn is related to the source where they are produced; for
instance, IgA is found in the mucous secretions, while the IgG is mainly found in
the blood and in tissue liquids. A functional difference between the various
isotypes is based on the part of the immunoresponse’s cascade of which they
are part. Between the 5 main isotypes shown in Figure 6 (IgG, IgA, IgE, IgD, and
IgM), the most common isotype in the human body is the IgG, which was also
used in this work.
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Figure 7. Heavy Chain Isotypes of Mammalian Antibodies. IgG provides the
majority of antibody-based immunity against invading pathogens

In general, antibodies that are synthetically produced can be classified in
two large groups: monoclonal and polyclonal. Polyclonal antibodies are obtained
from the sera of immunized animals, and they are a mixture of different
immunoglobulin types binding to multiple sites on the antigen used for
immunization [41]. On the other hand, monoclonal antibodies have a single
immunoglobulin type binding to a single specific site of a molecule (antigen,
protein, carbohydrate or nucleic acid) used for immunization.
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Figure 8. Monoclonal Antibody Production Diagram

Monoclonal antibodies are synthetically produced by the fusion of
antibody-producing mouse B cells, which have a finite life span, with
“immortalized” cells of a mouse myeloma (cancer cells). These fused cells are
cultivated and successful immortalized antibody producing cells are selected
[41]. This process is pictured in Figure 8. Each cell or clone obtained by this
method is capable of producing large amounts of a single type of antibody, which
binds to specific epitopes of the antigen molecule (Aß1-40, Aß1-42 or both).
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2.4.

Immunotherapy Preceding Work
Immunotherapy for treating AD is a subject that has been investigated

since the late 1990’s. Beka Solomon (1996) and her group were the first who
reported the effectiveness of N-terminus antibodies to block fibril formation in
vitro [42]. After this publication, many other studies involving immunotherapy for
AD were published from Solomon’s group and from other scientists all over the
world [43].
In 2003, preliminary results were published of the first clinical trial (ElanWyeth clinical trial) [44] in which patients with AD where vaccinated with
AN-1792 (purified Aß1-42), and after advancing to a Phase II (372 patients with
mild to moderated AD), the study was stopped after finding 7% of the patients
suffering from encephalitis. Nevertheless, the immunized patients were
monitored after the treatment was stopped and a reduction in cognitive decline in
comparison to the controls was found. This has been the basis to continue in the
search for an effective but safe immunotherapy treatment for patients with AD
[45].
It is important to note that immunotherapy can be classified in two types:
active and passive immunization (Figure 9). Briefly, active immunization can
take place either by injecting into the individual the whole antigen or part of it,
whichever way provokes an immune response resulting in the production of
specific antibodies to the injected antigen. The other type of immunization
consists of the injection of specific antibodies directed to the antigen of interest
(either monoclonal or polyclonal).
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Figure 9. Active vs. Passive Immunization. Adapted from Schenk, 2002 [27]

An ideal scenario for using immunotherapy to target a specific event
(clearance of Aß deposits) would be decreasing the body’s immune response to
a mild level, so that the external agent (antibody in the case of passive
immunization) could mediate the desired event in a controlled manner. From
here derives the idea of using monoclonal antibodies to trigger the clearance of
Aß deposits.
Indeed, this idea has been tested in mice, finding activation of the clearing
plaque mechanisms and cognitive recovery to a certain level [46-54]. But still the
key questions remain: What is the mechanism involved in this clearing event? Is
it possible to determine what antibody will activate and help the body to clear
these deposits in the most effective way? What about the quantities?
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The present study provides insights that help to understand, from a
molecular interaction point of view, the effect of the antibody on the plaques and
help to identify the species at different stages of the plaques formation and
clearance.

2.5.

Antibodies - Peptides Interactions Theories
For the purpose of this study it is important to consider the affinity between

the antibody and the A! peptide from a thermodynamic point of view. The affinity
is related to the type of interactions that occur at the interface between the two
molecules. In terms of energy, the affinity between two molecules will depend on
two thermodynamic factors, the enthalpy and entropy at the interface [55].
When antibodies and A! peptide molecules are free in aqueous solution,
they have a considerable configurational (translation and rotational energy,
measurable with ATR-FTIR spectroscopy) entropy that is lost when the
association (binding) occurs. This effect is observed in the analysis to be
presented in Chapters 4 to 6.
Moreover, the noncovalent interactions (H-bonds, salt-bridges and van der
Waals forces) between each molecule’s surface residues with the water are lost
when the antibody and Aß peptide enter in contact. Nevertheless, when the
bound water is released from the two interacting interfaces, it leads to an
increase in entropy of the solvent. Hydrophobic residues that become buried at
the interface cause an increase in entropy of the solvent in a similar way.
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However, at the same time, new hydrogen bonds, salt bridges, and van der
Waals interactions are formed between the antibody and the A! peptide [40, 56].
Energy losses and gains due to molecular interactions driving aggregation
can be indirectly detected as a function of integrated absorbance with ATR-FTIR
spectrometric analysis.
In addition, there are other factors that might also affect the molecular
interactions between the antibody and the A! peptide such as the presence of
salts (ions in solution) and the posttranslational modifications involving
morphological changes, as is the case of monomers, oligomers and fibrils
species adopted by the A! peptide [57].
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CHAPTER 3
ANALYTICAL TECHNIQUES AND MATERIALS

In this study, different analytical methods are combined to provide a
comprehensive physicochemical characterization and explanation of the
processes of peptide aggregation, as well as the effects produced by different
anti-Aß monoclonal antibodies when they are tested against Aß peptide
aggregates. This chapter explains the techniques used in a systematic way by
dividing them into physical, biochemical and chemical characterization. The
techniques explained here are brought into play in the subsequent chapters.

3.1.

Physical Characterization
These techniques served to evaluate the morphology of the samples by

studying their dimensions as well as dispersion and distribution of the different
peptide aggregates across the substrate’s deposition area.
Two physical characterization techniques were utilized: transmission
electron microscopy (TEM) and atomic force microscopy (AFM). The primary
aggregates of interest for the study were monomers, oligomers or protofibrils,
and fibrils.
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3.1.1. Transmission Electron Microscopy (TEM)
This is a microscopy technique that consists of a focused beam of
primary electrons that is directed through the sample under study. The electron
beam can be generated by thermionic
emission from a filament, commonly
tungsten. However, the electron’s beam
can also be produced by a lanthanum
hexaboride (LaB6) source. The electrons
are accelerated using electrostatic and
electromagnetic fields to focus the beam
and deflect it to a constant angle [58].
The instrument used was a
Morgagni-268D transmission electron
microscope from FEI Corporation (NE,
US), which is shown in Figure 10. The
source of primary electrons in this
instrument comes from the thermionic

Figure 10. Transmission Electron

emission of a tungsten filament. The

Microscope

instrument provides a point-to-point
resolution of 0.45 nm and a resolution between lines of 0.34 nm. It has a Soft
Imaging Mega 3 digital camera with an ultimate resolution of 1280x1024 pixels
per image. All processes of the specimen’s imaging takes place in a vacuum
chamber (10-6 Torr).
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The accelerating voltage chosen for the analysis was either 100kV or
60kV depending on the thickness of the sample, and it was adjusted to get the
best contrast.
The sample preparation depends on the specimen to be studied. For
instance, in the case of amyloid peptide, a drop (5 #L) of the sample is simply
placed on a special grid (rinsed with 5 #L of Millipore water) and dried with
ultrapure nitrogen.
In this study two different types of grids were used: Formvar coated grid
stabilized with evaporated carbon film (150 mesh, FCF150-Cu) and inert silicon
nitride grids (DuraSiNTM). The last one used to characterize the sample not only
with TEM but also with AFM. Both grids were purchased from Electron
Microscopy Science (PA, US), and they are shown in Figure 11 below.

Window
0.5x0.5-mm x-y

Diameter =3.05mm

(b) DuraSiNTM

(a) Formvar/Carbon
(150 mesh)

Figure 11. TEM Grids Used in this Work. (a) Carbon grid (150 mesh) coated
with Formvar film, a transparent and inert polymer. (b) DuraSiNTM, showing
window covered with silicon nitrate
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3.1.2. Atomic Force Microscopy (AFM)
This technique is also known as scanning force microscopy (SFM) or
scanning probe microscopy (SPM). It allows for the visualization of the
topographical structure of conductive and non-conductive materials. Commonly,
an AFM consists of a piezoelectric scanner, on which the sample rests; this
scanner allows movements in a precise fashion in the x, y, and z directions.
However, having the three-dimensional movement freedom in the same scanner
makes the instrument very sensitive to disturbances, resulting in long collection
times.
In this work, the AFM used (XE-100, Park Systems Inc., CA, US) consists
of two piezoelectric scanners; one scanner accounts for the x-y movements only,
and another piezoelectric scanner, located on the head where the cantilever
rests (Figure 12(a)), separately allows movement on the z direction. This new
design increases imaging flexibility and reduces the collection time. Another
important component in the AFM is a photodiode, which senses the movements
of the scanning tip when a laser positioned on it deflects due to its interaction
with the sample. This deflection is then translated by the photodiode into either a
current or a voltage, and ultimately into a digital image (Figure 12(b)).
With AFM, it is possible to image and characterize samples on a solid-gas
interface as well as solid-liquid interface. In this work images were collected in
both edia; however, primarily images were collected on solid-gas interfaces.
Atomic force microscopy allows characterization of the sample’s surface
by three different modes, as explained below.
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3.1.2.1. Contact Mode
In which the tip of the cantilever gets in touch with the sample (hard
materials).

3.1.2.2. Non-Contact Mode
Where the tip does not contact the sample. The non-contact mode is
used in characterization of soft materials (biological, i.e. cells).

(a) AFM, XE-100 Schematic

(b) Imaging Process

Figure 12. AFM and Scanning Process. The sample’s topology can be
studied by dragging a micro-scale cantilever across its surface. (a) Shows a
full diagram of the instrument; (b) illustrates a detail of the cantilever and
detection system on A! fibrils

3.1.2.3. Intermittent or Tapping Mode
This mode can be used to prevent the cantilever from being trapped by
capillary forces caused by the presence of an extremely thin film of water
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surrounding the sample in air. Also this mode is use to preserve the sample,
especially when biological samples are analyzed. Tapping mode was used to
analyze the Aß peptides deposited on mica.
Therefore, in this study tapping was the mode of preference for the
samples’ characterization. During the tapping mode, the cantilever is deliberately
excited by an electrical oscillator to amplitudes of up to approximately 100 nm,
creating an effective tapping modality as the cantilever travels over the sample
(Figure 12(b)). In addition, because the contact time of the tip with the sample is
relatively short, it is possible to reduce lateral force (that could cause distortion of
the image) and also preserve the sample’s morphology [59].
There are a wide variety of cantilevers commercially available; the
selection depends on the application and media. In this work, the cantilever used
was the type Tap300Al (Budget Sensors, Bulgaria). These cantilevers were
purchased with an aluminum coating to increase the laser’s reflectivity. This type
of cantilever has a resonant frequency of 300 ± 100 kHz and a force constant of
40 N/m.
The substrate material used to image the peptide’s samples was mica.
This is a preferred material when working with biological specimens [59]. Mica
was selected because it is atomically smooth (0.2 to 0.6 Å), and at the same
time, an easy to clean (sheets cleavage) and inert material. In this study natural
mica of the type ASTM V-1, purchased from Axim Mica (NY, US), was used.
The physical characterization methods used in this study facilitated
checking the physical size of the aggregates during time and determining the
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kind of secondary structures dominating at each stage of the aggregation
process of samples with anti-Aß monoclonal antibodies and alone.

3.1.2.4. General Protocol of Sample Deposition and Data Analysis
In this work all the samples were deposited under a laminar flow cabinet
(Class 100) to avoid contamination by settling of undesirable particles.
Each aliquot collected at specific times was diluted with Millipore water to
20 #M. Then, 5 µL of the diluted solution was deposited on freshly cleaved mica
and incubated for 5 min. A small Teflon O-ring (external $ 7mm, internal $
5mm) placed on the mica served to confine the peptide solutions. The excess of
peptide solution was flushed with 1 ml of Millipore water, dried with ultrapure
nitrogen, and stored in a vacuum dessicator at 30 in Hg for later AFM imaging.
As mentioned in Section 3.1.2, the images were taken with a XE-100
atomic force microscope from Park Systems Corp. (Santa Clara, CA) at 25°C.
The scans were performed with TAP300Al cantilevers (Budget Sensors,
Bulgaria) using tapping mode, to preserve the sample. The image resolution was
512x512 pixels, and the scan rate was 0.75 Hz, the set point of the cantilever
was variably moved to satisfy the image quality but never lowered beyond -0.260
#m. Images were collected at 5 random points on the mica surface, and each
point was imaged using three different scan sizes, first 35x35-#m x-y, then
zooming to 10x10-#m x-y, and finally to 2x2-#m x-y; this was done to assure a
fair exploration of the sample distribution across the mica.
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The processing and analysis of the images was performed with WSxM
software (version 5.0) [60].

3.2.

Biochemical Characterization

3.2.1. Aß Soluble Species Detection: SDS-PAGE and Immunoblotting
The combination of these two methods, SDS-PAGE (sodium dodecyl
sulfate polyacrylamide gel electrophoresis) and Western Immunoblotting allow for
discriminating the different soluble peptide species in the incubation solution
when separated by their difference in molecular weight.
In this sense, the sample, after being diluted in water and centrifuged, is
first analyzed with SDS-PAGE, in which the peptide is loaded on a 4-12% BisTris gel, and then exposed to an electrical current that allows the diverse
aggregates species to migrate and distribute on the gel at different speeds,
depending on their molecular weight. Normally, the gel used is polyacryamide.
This is an inert material, and serves only as a medium for the peptides to move
(under buffered conditions).
The peptide’s species recognition takes place once the peptide
(distributed on the gel) is carefully transferred to a polyvinylidene difluoride
membrane where it is likely to bind. A step prior to recognition is the “blocking”
step, in which either Bovine serum albumin (BSA) or non-fat dry milk are used to
prevent the interaction of the antibody with the unbounded sites of the
membrane, and therefore creates “noise”.
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The membrane is incubated with a primary antibody specific to N-terminal
of the peptide (Aß) by gentle agitation for 12 hours. Then, the gel is rinsed to
remove any unbounded primary antibody, and at this point, a second antibody
that targets the primary antibody is added to enhance recognition.
Finally, the immunostained peptides can be visualized using
chemiluminescence techniques. For the effect of this work, this step was
performed in accordance with the manufacturer’s recommendations (ECL,
Amersham, Denmark). Western blots images were captured with a Fujifilm Lass
300 Intelligent dark box scanner and quantified with a linear range of detection
using Alpha Ease software (AlphaEaseFC, Alpha Innotech Corporation, San
Leandro, CA). This analysis allows one to quantify the intensity of the bands
corresponding to the following: monomers species (4.5 KDa), Low Molecular
Weight (LMW) oligomers or protofibrils (14 to 21 KDa), High Molecular Weight
(HMW) oligomers or protofibrils (38 to 98 KDa), and larger soluble aggregates
(188 to 250 KDa). Figure 13 shows the schematic representation of the analysis
explained above.
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Figure 13. SDS-PAGE and Western Blot Schematic. It shows the steps
involved in the biochemical characterization of A! aggregates. The sample is
diluted and centrifuged, then exposed to an electrical current through a gel
separating aggregates by molecular weight, then the aggregates are
transferred to a membrane and immunotagged. The membrane is digitized
and the results are quantified with computer software

It is important to mention that during the peptide aggregation, monomers
associate as a paranuclei species (pseudostable) at the initial times of incubation
[61]. This paranuclei can be detected from the monomeric through the LMW
region. In the next chapter, this technique is linked to the physical view of the
different species and is also investigated with atomic force microscopy.
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3.3.

Chemical Characterization
Vibrational spectroscopy was used in this work to analyze and monitor the

chemical configuration changes of amyloid peptides. This technique also
allowed to determine and understand the effects of antibody molecules targeting
Aß peptide. While the experimental setup is relatively simple, the analysis of the
resulting data is rather complex. Hence, this section explains the most important
details to be considered for the analysis and further understanding of the results.

3.3.1. Attenuated Total Reflection - Fourier Transform Infrared
Spectroscopy (ATR-FTIR)

3.3.1.1. Principles
This technique is based on the combination of two main principles: the first
one is the detection of the vibrational energy emitted by the molecules when
excited by an infrared (IR) light; and the second principle is based on enhancing
the interaction between the molecules analyzed and the IR beam, therefore
improving the detection sensitivity of the method. The last principle, occurs by
using a crystal with high refractive index that allows the IR beam to undergo
multiple internal bouncing when entering the crystal in a 45° angle of incidence,
the beam creates an evanescent field at each point of contact with the sample’s
interface (Figure 14). The evanescent field created by the beam, approximately
penetrates the sample 1.66 #m in depth; distance measured at 1000 cm-1 for a
ZnSe crystal. This depth of penetration varies with the crystal used (ZnSe, Ge,
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diamond, etc), angle of incidence, and refractive index of the sample. In this
work all the experiments were performed using a ZnSe crystal as the ATR
element.

Bending

Stretching

Enhancement of the signal with an ATR crystal. The
evanescent field penetrates the sample 1.66 !m
approximately for a ZnSe Crystal

(a)

(b)

Figure 14. ATR-FTIR Spectroscopy Principles. (a) Two main and general
vibrational energies. (b) Schematic representation of an ATR accessory,
where the main element is a ZnSe crystal used to enhance the sensitivity of
detection. The crystal is beveled in the two edges where the beam enters and
exists in the crystal, allowing 12 points of contact with the sample. The
equation explains the depth of penetration that the beam has inside the media
under study, which depends on the wavelength of the energy, the angle of
incidence on the crystal, and the refractive index of both the sample and
crystal

The enhancement of the detection is of particular importance for this study
in which the concentration used is relatively small (100 #M).
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It is important to mention that ATR-FTIR spectroscopy works in the MidInfrared region of the electromagnetic spectrum (Figure 15), going from 400
through 4000 wavenumbers.

Figure 15. Electromagnetic Spectrum. The Mid-IR region is located between
400 and 4000 wavenumbers

The range can be slightly modified by the ATR crystal used. For instance,
in the case of ZnSe crystal the range goes from 650 to 4000 wavenumbers.

3.3.1.2. Peptides and Amide Vibration Modes
As explained in Chapter 2 section 2.2, amino acid residues formed the
peptides. The functional group of amino acids is the amide group, -C(=O)NH-.
Therefore, central vibrational energy characteristic of the peptides is the amide
type [6, 62, 63]. The Mid-IR region of the electromagnetic spectrum shows 5
regions correspond to the amide groups (Figure 16(a)).
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Figure 16. Amide Bands. Showing the mid-IR range going from higher
vibrational energy to lower: (a) All the amide bands encountered in the mid-IR
range, (b) Amide I, the most straightforward band holding the secondary
structure information of the peptide, (c) NH stretching and bending energies
are shown (NH stretching also is present in the Amides A and B). Amide II can
be related to protein absorption to the crystal, (d) Amide III region. The
example spectrum shown here corresponds to 5 days of incubation Aß40/42
Peptide
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From the amide bands or regions shown in Figure 16 the more relevant
are the amide I and amide II regions; ranging from 1600 to 1700 cm-1 and 1500
to 1600 cm-1 respectively. The amide I region, reveals the changes suffered by
the backbone of the peptide without neglecting the side group’s effects [64].
Because, interactions of the type NH and NH2 allow the peptide to anchor to the
crystal’s surface and this interactions are detected in the amide II region, this
interactions serve to investigate and understand the process of peptide’s surface
adsorption and desorption; simply by calculating the area under the amide II
region.
The amide I region is analyzed by its deconvolution in different peaks,
each corresponding to an existing secondary structures of the peptide. Table 1
summarizes approximately the ranges in which the secondary structures of
amyloid peptides are localized.
The amide I band is sensitive to the secondary structure change in peptide
and polypeptides [62]. However, explaining the large splitting into two bands of
antiparallel ß-strands structures, has become a challenge for researchers. In this
sense, some light on this issue has been shown by the use of the transition
dipole coupling mechanism theory [65]. This mechanism serves to explain how
the Aß structures split in two bands, one positioned with center at 1630 cm-1 and
the other center at 1690 cm-1. Other effect such as hydrogen bonding also
modifies the amide I frequency of the polypeptide.
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Table 1. Peak Assignment of Aß Secondary Structures. The assigned peaks
have been selected by gathering data from related literature [66, 67] and adapted
from the current study observations during secondary structure study
Range [cm-1]

Structure
Antiparallel ß-Strands
Low frequency, Intermolecular

1597-1630

High frequency, Intramolecular

1680-1710

Parallel ß-Sheets

1628-1640

Unordered

1640-1651

"-Helix

1650-1657

ß-Turns
Low frequency, Intermolecular

1657-1675

High frequency, Intramolecular

1680-1700

3.3.1.3. Hydrogen Bonding
The nature of hydrogen bonding has an evident effect on shifting the
position of peaks for different structures [68] as explained below.
The peak absorbance for structures in the amide I region correlates to the
strength of the hydrogen bonding; this is true for most cases except in the case
of the main frequency band of !-sheets. In descending order of hydrogen
bonding, the secondary structure bands are the following: intramolecular
antiparallel ß-strands extended chains (1610-1628 cm-1), intermolecular ß-sheets
(1630-1640 cm-1), "-helices (1648-1658 cm-1), 310-helices (1660-1666 cm-1) and
non hydrogen bonded amide groups in DMSO (1660-1665 cm-1) [69]. This
range is slightly varied from those shown in Table 1. However, at the moment of
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the analysis both are considered. The peak frequency of the amide I group is
lowered by 20 to 25 cm-1 and is influenced by the two possible hydrogen bonds
connecting to the C=0 group.
In the case of polypeptides, experiments indicate that amide I main
absorption band can vary by 30 cm-1 because of different hydrogen bond
strengths among peptide residues.
Alpha-helices hydrogen bonding to solvent influences absorption frequency
by approximately 20 cm-1; solvated "-helices induce a 20 cm-1 lower
absorbance maximum for amide I.

3.3.1.4. Transition Dipole Coupling Mechanism (TDC)
It is a resonant mechanism that causes secondary structures to influence
amide I absorbance frequencies. Transition Dipole Coupling (TDC) is dependent
on distance between amide groups in a peptide chain, and it is caused by
resonance interaction due to oscillation of dipoles of such neighboring amide
groups. TDC manifests itself in two ways on the FTIR spectra [70, 71] and is
explained as follows.

3.3.1.4.1. Exciton Transfer
In an analogous way to fluorescence (Förster) resonance energy transfer
(FRET), energy is absorbed and transmitted to nearby structures delocalizing
excitation states over a length of 8 Å; typically exciton transfer energy for "-helix
has a constant of 0.5 ps (pico seconds).
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3.3.1.4.2. Exciton Splitting
Additionally, TDC results in the splitting of bands since coupled oscillators
result in different excitation energy levels in phase and out of phase. This, results
in the splitting of the absorbent contribution on amide I for the case of antiparallel
!-sheet structures, with an approximately separation of 70 cm-1.

3.3.1.5. General ATR-FTIR Data Analysis Protocol
Each spectrum collected with ATR-FTIR spectroscopy was smoothed and
baseline corrected in Omnic (version 7.2a, Thermo Fisher Scientific). The
spectroscopical regions of interest were the amide I (1600-1700 cm-1) and amide
II region (1500-1600 cm-1). To the amide II region the area under the curve was
simply calculated and this value represented the absorption or desorption of the
peptide to or from the crystal respectively.
The amide I region (1597-1710cm-1) was selected and saved in Comma
Separated Values (CSV) format. The file was then analyzed with OriginPro
(version 8 SR5, OriginLab). In OriginPro the analysis was perfomed by peak
fitting using the parameters shown in Table 2. This operation is known as
spectrum’s deconvolution by interactive least-squares curve-fitting technique,
using a Gaussian distribution model.
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Table 2. Fitting Parameters and Boundary Conditions
N°
0
1
1
1
2
2
2
3
3
3
4
4
4
5
5
5
6
6
6
7
7
7

Meaning
offset
center
width
amplitude
center
width
amplitude
center
width
amplitude
center
width
amplitude
center
width
amplitude
center
width
amplitude
center
width
amplitude

Value
LB Value
0
1614.8125
1597
8
1
0.0097
0
1628
1628
8
1
0.01229
0
1640
1640
6.11721
1
0.00483
0
1651.05348
1650
6.35162
1
0.0033
0
1664.41119
1657
6.93525
1
0.00224
0
1676.44412
1670
7.39482
1
0.001
0
1685.63946
1680
5.59086
1
5.19289E-4
0

LB Param UB UB Value
y0
<=
xc_1
<=
1630
<=
w_1
<=
8
<=
A_1
<=
xc_2
<=
1640
<=
w_2
<=
8
<=
A_2
<=
xc_3
<=
1651
<=
w_3
<=
8
<=
A_3
<=
xc_4
<=
1657
<=
w_4
<=
8
<=
A_4
<=
xc_5
<=
1675
<=
w_5
<=
8
<=
A_5
<=
xc_6
<=
1690
<=
w_6
<=
8
<=
A_6
<=
xc_7
<=
1710
<=
w_7
<=
8
<=
A_7

The resulting peaks after the curve fitting represent the contribution of
each secondary structure, this quantity is calculated by determine the area under
each fitted peak, and consequently the addition of these peaks represent the
amide I region. Each peak is assigned as a particular structure depending on the
position. In this way it is possible to monitor the secondary structure percentage
(as a normalized value) and the raw value. The latest value can be related to the
kinetic of each particular secondary structure followed with time. An example of
this fitting is shown in Figure 17.
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Figure 17. Sample’s ATR-FTIR Data Analysis. It Depicts A!1-42 after 48 hours
of incubation. The colored areas correspond to the estimated contribution of
each specific structure to the total absorbance calculated by deconvolution of
the amide I region. Also the amide II region is shown and it represents the
surface protein adsorption

It is important to mention, that in previous studies (Jimenez, 2005 [72]) the
investigation of the amide I has been performed considering the band
assignment in a more general fashion. Assuming only one frequency of
antiparallel ß-sheets (called intermolecular interactions, 1610-1625) and
considering the high frequency range (1670-1700 cm-1) as ß-turns. In this new
study to give to the antiparallel ß-sheets structure the importance they have and
to understand the role they play during aggregation/dissolution of the peptide the
bands assignment in the amide I region has been judiciously modified assigning
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ß-turn to a range of 1670-1690cm-1 and a introducing a new band between 16801710cm-1 corresponding to high frequency antiparallel ß-sheets [73, 74].

3.3.1.6. Some Relevant Consideration for the ATR-FTIR Analysis
In order to understand the possible molecular interactions taking place in a
solution and related to the absorption energies present at determined points of
the spectra, it is important to consider the following important phenomena.

3.3.1.6.1. Protonation or Deprotonation
For instance, at pH 7.4 the Aß1-40 and Aß1-42 are deprotonated (see
Appendix A), having a net charge (theoretically) of -2 and -3 respectively. This
unbalance of net charge contributes to the conformational change of the peptide
molecules as well as their absorption energies.

3.3.1.6.2. Chemical Properties of Neighboring Groups
For instance amide group, allows for localizing a particular absorption
band and differentiating it from a C=O originated from an aldehyde or ketone
group. In this work this is not relevant because it is known that only peptides
would be showing this C=O bonding.

3.3.1.6.3. Bond Angles and Conformations
Under the effect of Coulomb interactions, proteins modify their bonding
angles; this affects the three-dimensional structure of their backbone originating
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changes (conformational changes). This combination is responsible for the amide
I band sensitivity to secondary structure.

3.3.1.6.4. Hydrogen Bonding
Another important interaction encountered in peptides is the hydrogen
bonding; this type of interaction stabilizes the peptide molecules in their lower
energy state depending on the media conditions. The strength of hydrogen
bonding can be directly observed as mentioned earlier in section 3.3.1.3.

3.3.1.6.5. Conformational Freedom
A very important aspect of FTIR spectroscopy is the fact that as structures
are more flexible, the band that they represent in the vibrational spectrum is
wider. Heterogeneity of structures caused by conformational freedom results in
broader spectrum bands defining structures. On the other hand, more rigid
structures have less conformational freedom and result in tighter spectrum
bands. When structures interact through binding, conformational freedom is
usually reduced; this is also the case for molecules binding peptides and proteins
and for peptide-peptide binding, resulting in the reduction of bandwidth by a
factor of two [75]. The incremented rigidity and reduced conformational freedom
sometimes increases rigidity in distant parts of large molecules such as proteins
as well.
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3.3.1.6.6. Overlap of Conformational Changes in the Spectrum
The fact that different structures overlap in the spectrum makes analysis
of signals more complex. However, spectra can be subtracted, with the limitation
that the infrared difference spectrum reveals only the net change of secondary
structure. In this work, by amide I deconvolution it is possible to distinguish the
structures during overlapping of conformational changes.

3.3.1.6.7. Rigid Domain Movement
Movements of relative large structures are not detected in near infrared
spectra. Hinge regions of proteins are an interesting example in which the larger
rigid domains are not detected while the hinge flexible region is prevalent in the
spectra. An example of two rigid domains moving about a flexible domain is
shown in Figure 18 (black line). In this case, the detection of the flexible domain
would be prevalent, established by comparing it to the larger and more rigid
domains attached to it. The detection would be limited to the conformation of the
relative orientation of neighboring amide groups in the flexible domain.
However, there is increased sensitivity in the detection of conformational
changes where the backbone portion of a molecule is intimately linked to flexible
domains; for example, if an "-helix shortens, there are changes not only in the
amide modes of the unwinding backbone portion, but also in others amides
related to the remaining portion of the helix.
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3.3.1.6.8. Subtle Changes within Secondary Structures
Finally, subtle changes within secondary structures, such as twists in ßsheet, bending of an "-helix, or hydrogen bonding to backbone carbons, are
detectable in the amide I of the mid-infrared spectrum.

Figure 18. IR Spectrum Analysis and Rigid Domain Movement.
Adapted from Barth 2007 [76]

3.3.1.7. General Experimental Methodology
The experiments were performed with a 6700 Nicolet spectrometer
(Thermo Fisher Scientific, US). Two different accessories were used: an ATR
trough plate for the study of monomeric solutions (with more flexibility to
evaporate and redissolve the peptide’s in different solvents), and a closed ATR
flow cell accessory for the peptide solution in HFIP, and the oligomeric and
fibrillar solutions (hermetically closed to avoid evaporation during long incubation
times, and with temperature controller).
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The IR beam was focused at normal incidence onto one of the 45°
beveled faces of the ATR zinc selenide (ZnSe, ns = 2.4) trapezoidal crystal,
where the IR beam undergoes multiple internal reflections resulting in signal
enhancement. A crystal made of ZnSe was the preferable used because of its
low reflection losses in the infrared [77], wide infrared range (between 20,000
and 650 cm-1), compatibility to aqueous solutions, and chemical inertness
(Appendix B).
After each measurement, the flow cell was dismantled and thoroughly
cleaned with isopropyl and Millipore water; in addition the crystal was exposed 5
minutes to UV to eliminate organics, and rinsed again with Millipore water. All the
flow cell parts were finally dried with an ultrapure nitrogen stream and reassembled.

3.3.1.8. General Data Analysis
For the cases of long incubation times (i.e., 24h, 48h, or longer) and with
several spectra collected by hour (i.e., 6 spectra per hour), high variability is
recorded from spectrum to spectrum. For these cases, set of spectra with time
ranges of 4 hours were averaged and the variance among them was calculated.
To calculate the average absorbance (Eq.1) for a time frame (for example
4 to 8 hours), all curves under that timeframe are added and averaged by the
number of curves recorded during that time; this yields an average spectrum:

47

tn
" Absorbance(t)
t
Average Absorbance(w) = 1
n

(Eq. 1)

!

The software calculates then the variance for the curves during that time
frame as Eq.2 shows:

tn
2
# Absorbance(t) " Average Absorbance
t
Variance(w) = 1
n

(

!

)

(Eq. 2)

Finally, the number to calculate the Relative Spectral Variance (Eq.3), the
variances (Eq.2) for each wavelength in the region are integrated to calculate the
area under the variance curve, divided by the average absorbance (Eq.1), and
multiplied by 100.

wn
" Variance(w).dw
w1

Relative Spectral Variance = w
* 100
n
" Average Absorbance(w).dw
w1

!

(Eq. 3)

This relative spectral variance or %Variance is a good indicator of stability
of the processes undergone by Aß peptides in their stabilization at different
conformations; typical values for stable Amide I and Amide II regions are around
10%; as shown in Figure 30.
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3.4.

Reagents
Table 3 lists all reagents used in this work.
Table 3. Reagents Used in this Work

Reagent
1,1,1,3,3,3-Hexafluro-2Propanol (pa: >99%),
HFIP
Methyl Sulfoxide
Anhydrous (p:>99%),
DMSO or Me2SO
Tris (Crystallized)
p:>99%)
Phosphate-buffered
saline, PBS
Hydrochloric Acid, HCl
Nitrogen

Manufacturer Description
Fisher Sci.
Very volatile transparent liquid
Acros

Viscous transparent liquid

Fisher Sci.
BP152-500
SigmaAldrich,
P3813
Acros
124630010
Airgas
NI UHP300,

White powder
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White powder

Ultrapure gas

CHAPTER 4
AGGREGATION PATHWAYS OF AMYLOID BETA PEPTIDE

Amyloid beta (Aß) peptides and proteins in general modify their molecular
configuration (i.e., secondary structures) influenced by the media conditions in
order to minimize their overall energetic state [78, 79]. This chapter will analyze
and discuss how media conditions affect the secondary structure of Aß peptides.
The conditions evaluated here have been used to identify features corresponding
to each Aß species during aggregation. The species studied are: monomers,
which are the single molecules of Aß peptide characterized by their hydrophobic
character (Aß1-42 in particular); oligomers, which are found during the nucleation
or seeding state and that are also known as the intermediate species during
fibrillization [80]; and finally the fibrils, the main components of neuritic plaques in
Alzheimer’s disease brain tissue. In later chapters the findings from this chapter
will be used as guidelines to elucidate changes in aggregation and effects of
antibodies on the Aß peptide species.

4.1.

Protocols and Methods
Each peptide in this study, Aß1-40, Aß1-42, and their equimolar mixture

Aß40/42, were prepared following a common protocol explained below.
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4.1.1. Peptide’s Homogenization
Amyloid Beta (Aß) peptides were purchased from American Peptide INC.
(Sunnyvale, CA). Table 4 below shows the general specifications of Aß peptides
used in this study.
The peptides were homogenized and aliquoted in HFIP, as described by
Stine et al. 2003 [37]. Briefly, HFIP was injected into the peptide’s flask using a
gas-tight Hamilton glass syringe with a Teflon plunger, at a peptide’s
concentration of 1 mM.

Table 4. General Specifications of Amyloid Beta Peptides Used in this Study
Aß1-40
(Amyloid Beta 1-40)

Aß1-42
(Amyloid Beta 1-42)

Sequence

Asp-Ala-Glu-Phe-ArgHis-Asp-Ser-Gly-TyrGlu-Val-His-His-GlnLys-Leu-Val-Phe-PheAlabh-Glu-Asp-Val-GlySer-Asn-Lys-Gly-Ala-IleIle-Gly-Leu-Met-Val-GlyGly-Val-Val

Asp-Ala-Glu-Phe-ArgHis-Asp-Ser-Gly-Tyr-GluVal-His-His-Gln-Lys-LeuVal-Phe-Phe-Ala-GluAsp-Val-Gly-Ser-AsnLys-Gly-Ala-Ile-Ile-GlyLeu-Met-Val-Gly-Gly-ValVal-Ile-Ala

MW (a.m.u.)

4,329.9

4,514.1

Formula

C194H295N53O58S1

C199H307N53O59S1

Purity (HPLC Analysis)

97.2%

87.2%

Solubility

1mg/ml in water

1 mg/ml in 0.05M Tris
buffer

Counter ion

Trifluoroacetate

Trifluoroacetate

Characteristic

American Peptide Cat. No. 62-0-78

62-0-80
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The peptide immediately dissolves because of the high polarity of the
HFIP, that helps to break down the peptide’s pre-existing tertiary structures [37].
After 10 minutes in HFIP at 25°C, the peptide was aliquoted in sterile
microcentrifuge tubes and left overnight in a laminar-flow cabinet (Class 100)
allowing the HFIP to evaporate. This protocol created a clear peptide film in the
bottom of each vial. Each film was also exposed to 30 in Hg of vacuum for 8
hours to eliminate traces of HFIP and humidity. Each vial was closed with
nitrogen (gas), and sealed with Parafilm-M. Finally, all the vials were stored at 20°C in a jar containing molecular sieves and closed with nitrogen to maintain a
low humidity environment.

4.1.2. Aß Monomers under Different Media Conditions
Figure 19 illustrates the protocol followed to understand and identify the
initial molecular conformation and morphology of Aß peptides under media
conditions that at different incubation times promote defined monomers,
oligomers, and fibrils. Aß1-40, Aß1-42, and Aß40/42 peptides were exposed to the
conditions explained below and monitored until stability was reached. That is,
the peptides were monitored 30 minutes at conditions (a)-(c); and for 1 hour at
conditions (d) and (e).
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Figure 19 explains the details of this study as follows:
Figure 19(a): each peptide was dissolved in HFIP at 1mM concentration,
as described in the pre-treatment step (section 4.1.1), and allowed to equilibrate
for 30 minutes in a gas tight ATR flow cell. Continuous spectra were collected
during this period.
Figure 19(b): Once the HFIP evaporates a film is formed, it was
determined if monomeric species were maintained. Thus, in a second experiment
each peptide dissolved in HFIP as described in Figure 19 (a) was deposited on
an open ATR trough plate. Then, the HFIP was removed by evaporation assisted
by a dry nitrogen (gas) stream. Continuous spectra were collected for each
peptide film during 30 minutes. In addition, a 5 #l drop of this solution was
deposited on freshly cleaved mica and the film was later imaged with atomic
force microscopy (AFM) to relate peptide’s structure to its morphology.
Figure 19(c): When oligomers or fibrils are prepared, the peptide’s film is
always re-dissolved in DMSO to 5 mM concentration.
Figure 19(d): The above solution (c) is taken to 100 #M (0.1 mM) using 20
mM Tris buffer solution (2.42g Tris Base pH 7.4 w/HCl, prepared in 1L of
solution) to prepared oligomers.
Figure 19(e): To prepare fibrils, solution (c) is diluted to 100 #M with 0.01
M phosphate-buffered saline solution.
AFM was used to analyze the morphology of Aß1-40, Aß1-42, and Aß40/42,as
prepared in Figures 19(d) and 19(e).
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Figure 19. Systematic Study of Aß Monomers under Different Media Conditions.
(a) Aß peptide is dissolved in HFIP and monitored with ATR-FTIR spectroscopy;
(b) the HFIP is evaporated from the peptides’ solution leaving a film; (c) the
peptide’s film is redissolved with DMSO; (d) The peptide dissolved in DMSO is
diluted to 100#M with TRIS solution to obtain stable oligomers; (e) The peptide
dissolved in DMSO is diluted to 100#M with 0.01M PBS solution to obtain fibrils

4.1.3. Oligomers Stability and their Characteristic Secondary Structure
The morphology and secondary structure dynamics of the oligomeric
intermediate species of the Aß peptides was characterized. The oligomers were
prepared following a method established in a preliminary study [81]. Briefly, the
peptide film was dissolved in DMSO (5 mM) and diluted to 100 #M (0.1 mM) with
a 20 mM Tris buffer solution (2.42 g/L Tris Base at pH 7.4 adjusted with HCl).
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The solution prepared to form oligomers was split in two portions, one
portion was injected in an ATR flow cell to follow in situ the evolution in
secondary structures at 25°C; the second portion of the oligomeric solution was
aliquoted and incubated at the same temperature (25°C); each aliquot was
retrieved at different times during 48 hours for later AFM analysis.

4.1.4. Aß Species and Kinetics of Fibril Formation
The first step to promote fibril formation was to re-dissolve the peptide film
with DMSO until it reached concentration of 5 mM, the dissolution process was
assisted by 5 minutes of sonication. This was followed by the addition of PBS
(0.01 M, pH 7.4), diluting the peptide solution to 100 #M. After 1 minute of
sonication the solution was split in two portions, the first one was injected in the
ATR flow cell for spectroscopy analysis (incubated at 25°C) and the second
portion was aliquoted for AFM analysis. Aliquots retrieved at different time points.

4.1.5. Peptide Secondary Structure Study: Attenuated Total Reflection
Fourier Transform Infrared (ATR-FTIR) Spectroscopy
Once the accessory was assembled and prior to injecting the peptide
solution, a portion of fresh peptide-free incubation media solution was flushed
through the cell in each new experiment. Spectra and background of this media
in contact with the crystal were obtained. The peptide-free solution background
was used to eliminate the solvent contribution in the peptides solutions. The
experiments were run for 30 minutes for monomer characterization, and for 48
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hours for oligomeric and fibril formation. Oligomers and fibrils solutions were set
up to collect a new spectrum every 10 minutes.

4.2.

Results, Analysis and Discussion
This section shows and discuses the particular characteristics of the Aß

species, beginning with the monomeric species of the two isoforms Aß peptides
(Aß1-40 and Aß1-42) and their equimolar mixture; moving on to the oligomers and
fibrils characterization for each peptide.

4.2.1. Species of Aß Peptides
During peptide aggregation different species can be found and defined.
However, referred here as monomer, oligomers, and fibrils as species of the Aß
peptide.

4.2.1.1. Aß Peptide Monomers
This first study was designed to determine the characteristic content of
secondary structure present in the monomeric specie of Aß peptides.
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Figure 20. Amide I and II Regions of Aß1-40 Monomers in HFIP. The spectra
displayed here were collected for Aß1-40 during 30 minutes of incubation in HFIP
at 1mM. The amide I region shows that the antiparallel ß-sheet are the dominant
structures within the monomeric species. The lack of absorbance in the amide II
region is evidence of the absence of protein adsorption, hence all the monomeric
species are in solution

Aß1-40 peptide dissolved in HFIP was injected in a hermetic ATR flow cell
accessory and monitor over 30 minutes with ATR-FTIR spectrometry. Figure 21
shows that monomers are unequivocally detected in HFIP, confirmed by the lack
of protein adsorption revealed by the amide II region.
After deconvolution of the amide I region for each time shown in Figure 20
with clear center in the antiparallel ß-sheet band (1624 cm-1), it is possible to
obtain the information plotted in Figures 21(a) and 21(b), showing the evolution
of secondary structures during 30 minutes of incubation.
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Figure 21. Secondary Structures of Aß1-40 Monomers in HFIP. (a) Secondary
structures evolution of the monomers in solution. (b) Secondary structure content
change for the monomeric species. Each point in this plot was calculated by
integrating the area under the curve corresponding to the different specific IR
bands defining each secondary structure (Shown in Table 1) at the times shown
in (a). Observe in that after 10 minutes the structures start reaching equilibrium
and between 27 and 30 minutes stabilize

Figure 21(a) shows the increase of antiparallel and parallel ß-sheets
secondary structures during 30 minutes of incubation in HFIP, this figure
suggests that the monomers are constantly evolving but they do not aggregate.
However the dominant configuration of the monomeric species is the antiparallel
ß-sheet type, Figure 21(b).
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Figure 22. Secondary Structure Content of Aß1-40 Peptide Monomeric Film. (a)
The shift of amide I and the appearance of amide II show a significant difference
when protein adsorption occurs. (b) Comparison of secondary structure content
change before (light color bars) and after (solid bars) HFIP has evaporated. Main
differences are observed, as the switch from antiparallel ß-sheet structures to
parallel ß-sheets with a larger influence of "-helix structures

Continuing with the study of Aß1-40 peptide, once the HFIP solvent
evaporates, it leaves a film with characteristic secondary structures, shown in
Figure 22. The shift of the amide I region in this figure confirms that when the
peptides absorb to the crystal, parallel ß-sheet structures are highly involved in
this process.

Protein adsorption (film formation) is verified by analyzing the

amide II region (Figure 22(a)).
Figure 22(b) compares the content of secondary structures of the peptide
before and after the HFIP is evaporated (film formation). The monomeric film is
characterized by the dominant content of parallel ß-sheets and "-helix structures,
with decrease of antiparallel ß-sheet structures, this confirms that the peptide is

59

not in solution anymore. It is important to note that the antiparallel ß-sheet
structure was significantly reduced as the film was formed.
The results for Aß1-40 shows that 30 minutes (Figure 21(b)) is a reasonable
incubation time in HFIP for the peptide (also found for the cases of Aß1-42 and
Aß40/42) to have its secondary structure in equilibrium. The two peptides and their
1:1 combination under study (Aß1-40, Aß1-42 and Aß40/42) were incubated for
30 minutes in HFIP as an initial practice for all experiments involving these
peptides. Comparison of the monomeric species in HFIP for Aß1-40, Aß1-42 and
their equimolar combination is shown in Figure 23.
It is important to note that Aß1-42 peptide shows an antiparallel ß-sheet to
"-helix ratio close to 1 (0.85) in its monomeric state. In previous work (Jimenez,
2005 [72]) "-helix structures were found to play an important role during fibril
formation of Aß1-42 peptide. Hence, it is not surprising to find antiparallel ß-sheet
structures competing with "-helix structures in its monomeric state.
Prion proteins capable of amyloid formation exhibit similar characteristics
when forming fibrils; with similar roles played by antiparallel and "-helix
structures. This is evidenced in a NMR study performed to the prion protein
domain PrP(121-231). This domain contains most of the point-mutation sites
known to infectious prion proteins that form two-stranded antiparallel ß-sheet and
three "-helices [82].
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Figure 23. Secondary Structure of Amyloid Peptides Monomers in HFIP. (a)
Amide I region, spectra corresponding to 30 minutes of incubation in HFIP for
Aß1-40, Aß1-42, and Aß40/42. (b) Secondary structure content corresponding to the
monomers of Aß1-40, Aß1-42, and Aß40/42 in HFIP. The values shown in this plot
were obtained by averaging the spectra shown in (a) and the error bars are the
standard deviations. Notice that, antiparallel ß-sheet (blue) is the dominant
structure in Aß1-40 and Aß40/42 monomeric species. When in the case of Aß1-42
both antiparallel and "-helix (green) structures dominate the monomeric species
(c) Schematic approximation of two Aß monomers mainly showing antiparallel ßsheet and small regions of "-helix structures (image representing the dimer of
transthyretin, shown with permission of Landry, 1996)

The results found in this study, revealed the importance of antiparallel
structures to stabilize folded monomers in solution. Note that one would find
parallel ß-sheet structures as well as part of the overall structure. However, the
dominant secondary structure in all 3 cases is the antiparallel ß-sheet. This
observation, is in agreement with the name given to the Alzheimer’s disease
amyloid peptide, that is amyloid “Beta” peptide, due to the high content in ß-sheet
structures in its monomeric folded state [83, 84]. Figure 23(c) is an schematic
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approximation of two amyloid forming monomers, with permission of Landry,
1996, this picture represents the antiparallel beta sheet in equilibrium with small
domain of "-helix structures. This model is in agreement with our results.
The study performed to Aß1-40 of HFIP evaporation (Figure 22) and film
formation, was repeated for Aß1-42 and the peptide equimolar mixture Aß40/42, the
results comparing the secondary structure content for each case are shown in
Figure 24.

Figure 24. Change in Content of Secondary Structure for Amyloid Peptides
during Monomeric Film Formation. (a) Amide I and II regions for Aß1-40, Aß1-42,
and Aß40/42. (b) Comparison of secondary structure content before and after the
HFIP evaporates, Aß peptides dissolved in HFIP (light color bars) versus their
films (solid bars)
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In general, Figure 24(a) shows that when a film is formed, there is a
significant shift in the secondary structures (amide I), and a prominent absorption
in the amide II region. Figure 24(b) shows that the deposition is mainly
dominated by parallel ß-sheet structures, while the monomeric state in solution is
dominated by antiparallel ß-sheet structures.
Figure 25(a) shows the characteristic morphology of Aß1-40 and Aß1-42
monomeric films; which were obtained by depositing the peptide dissolved in
HFIP on freshly cleaved mica as explained in 3.1.2.1. Figure 25(b) shows the
height distribution analysis for the films from Figure 25(a) corresponding to Aß1-40
and Aß1-42 peptides. Aß1-42 peptide formed more dense films than Aß1-40, this can
be explained by the hydrophobic nature of Aß1-42 peptide, which reduces steric
interaction promoting a denser film. Two other studies (Harper in 1997, and
Shao in 1999) are in agreement with the hydrophobic nature and ability to pack
conferred to Aß1-42 peptide [85, 86].
In addition to these studies with HFIP, Figure 26 shows the results after
the peptide films are redissolved with DMSO, since this is the protocol followed
prior to oligomeric or fibrillar preparations.
As Figure 26 shows the action of DMSO is to redissolve the peptide and
stabilize the secondary structure content. However, when oligomeric and fibrillar
solutions are prepared, sonication is an important step to ensure the
redissolution of the film. Notice that the film after DMSO addition shown in
Figure 26 was not sonicated.
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Figure 25. Morphology of Monomeric Peptides Film. (a) AFM image of Aß1-40
(top) and Aß1-42 (bottom) peptide monomers on mica (scan size: 0.5x0.5-#m x-y);
(b) Gaussian distribution of the heights found in each case (topography), please
observe that the Aß1-42 film has a less dispersed distribution (red line, centered at
1nm)

In general, this study has proven that when peptides are pre-treated with
HFIP, their conformations in solution are reduced to their monomeric form. This
results in a homogeneous (monomeric) film when the HFIP is allowed to
evaporate. This is the rationale for pre-treating the peptides with HFIP as a
homogenizing point prior to prepare any peptide solution.
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Figure 26. Spectroscopy Analysis for Aß Peptide Monomers in DMSO. (a) Amide
I and II regions for Aß1-40, Aß1-42, and Aß40/42, the amide I region shows that the
peptides dissolved in DMSO are structurally stable (no shift), the absorption
observed in the amide II region shows that there is peptide remaining as a film.
(b) Secondary structure content by peptides, comparison between the dry
peptide film (light color bars) and the peptide redissolved in DMSO solid bars).
Note that in all three cases antiparallel ß-sheet structures increased in DMSO

4.2.1.2. Oligomeric Species of the Aß Peptides
Oligomers are the intermediate species in the formation of fibrils [87].
Understanding the stability and secondary structure characteristics of these
species is key to explain fibril formation and disruption (which will be discussed in
chapters 5 and 6 in detail). This study also characterized the kinetics of
secondary structures responsible for the formation and stability of oligomeric
species of Aß peptides. The study is presented by peptide type.
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4.2.1.2.1. Oligomers of Aß1-40 Peptide
Two stages of the oligomerization process were monitored in this study.
First, the peptide dissolution and hydration taking place in the initial 60 minutes of
incubation (Figure 27); and second, the formation and stabilization of the
oligomeric species during 48 hour of incubation (Figure 28).
Molecular rearrangement is observed in the first 60 minutes of incubation
(Figure 27). During the first 10 minutes antiparallel ß-sheets and "-helix are the
dominant structures; at this point monomers are mainly in solution. After 10
minutes of incubation, the structures shift with increase in parallel ß-sheets
structures, this is the moment that marks the beginning of the oligomerization
process (Figure 27(c)).
Figure 28 (a) shows the spectra corresponding to 48 hour of total
incubation, represented by the multicolored lines. Figure 28(b) shows the same
48 hour of total incubation in grey but representing time ranges of 4 hours in red.
This visualization technique provides a quick way to observe progressive spectral
changes, and assess variance visually; for the whole amide spectra, or for the
amides I and II independently.
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Figure 27. Spectroscopy Study of Aß1-40 Peptide during the First 60 Minutes of
Incubation in DMSO+TRIS Solution at 25°C. (a) Amide I and II regions, spectra
from 0 to 60 minutes, amide II shows protein adsorption, on amide I region
shifting can be observed showing secondary structure instability. (b) Comparison
of the total integrated absorbance of amide I vs. amide II from 0 to 60 minutes.
(c) Reorganization of the secondary structure that assists the process of
aggregation into stable oligomers. (d) Evolution of secondary structure content
of Aß1-40 the first 60 minutes of incubation
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Figure 28. Kinetics of Aß1-40 Oligomers in DMSO+TRIS Solution at 25°C. (a)
Spectra of the Amide I and II regions for Aß1-40 peptide during 48 hours of
incubation at 25°C. (b) Sets of spectra selected each 4 hours (red spectra),
during 0 to 48 hour of incubation

Figure 29(a) shows the average spectra calculated from the time frames
shown in Figure 28(b). The average spectra were calculated using (Eq.1) from
Section 3.3.1.4. Figure 29(b) shows the %Variance calculated with (Eq.3) also
from Section 3.3.1.4.
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Figure 29. Aß1-40 Average Spectra and Variance Percentage. (a) Spectra
obtained from averaging the 4 hours range as shown in (Eq.1); (b) %Variance for
each time point corresponding to Amide I and II separately and individually,
observe that when values are under 30% of variance (Eq.3) the calculation is
considered to be statistically acceptable, more variability than this values reflects
instability of the sample in that range of time

The analysis of the amide I and II regions for Aß1-40 peptide incubated in
DMSO+TRIS solution is shown in Figure 30(a), it represents the behavior of
Aß1-40 during the formation of stable oligomeric species during 48 hours. (b)
Shows the changes exhibited by the amide I and II regions each 4 hour time
frame (averaged spectra) with overall activity in secondary structure (amide I)
and adsorption (amide II). As the deconvolution of amide I spectra reveals in (c),
all secondary structures increase for every structure in absolute absorbance
values. However, when these values are normalized Figure 30(d) reveals that the
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overall content of parallel structures increases while antiparallel structures
decrease during the formation and stabilization of Aß1-40 oligomers.

Figure 30. Analysis of the Amide I and II for Aß1-40 Oligomers in DMSO+TRIS
Solution. (a) Averaged spectra using (Eq.1) from Section 3.3.1.4. (b) Change of
integrated absorbance under the amide I and II during the incubation period. (c)
Secondary structure kinetics of Aß1-40 in DMSO+TRIS during 48 hour of
incubation. (d) Change in secondary structure content for Aß1-40 in DMSO+TRIS
during 48 hour of incubation
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Figure 31. Morphology of Aß1-40 Oligomers over 48 Hours of Incubation. (a) 1x1#m x-y scans of Aß1-40 from 0.5h to 48h of incubation. (b) Average diameter of
the oligomers encountered in solution at different incubation times

Figure 31(a) shows the morphology of Aß1-40 oligomers through time,
these images have a scan size of 1x1-!m x-y. Results in Figure 31(b) show the
average diameter of the oligomeric species shown in Figure 31(a), and it can be
observed that these species maintained their structure and shape over 48 hours
incubation in DMSO+Tris (2:98 volume to volume) at 25°C.

4.2.1.2.2. Oligomers of Aß1-42 Peptide

As in the previous study (4.2.1.2.1), this section investigates the stability of
Aß1-42 oligomeric species using two timeframes: during the first hour (Figure 26)
of incubation (in DMSO and TRIS solution at 25°C, Figure 32) and during 48 hour
to monitor stability.
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Figure 32. Change of Secondary Structures of Aß1-42 Dissolved in DMSO after
Diluting with TRIS Buffer Solution to 100 #M. (a) Spectra of the Amide I and II
regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I
region shifting can be observed showing instabilities; (b) Comparison between
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c)
Reorganization of the secondary structure that trigger a process of aggregation
into oligomers is shown; (d) Change of secondary structure content of Aß1-42 in
the first 60 minutes of incubation

Figure 32 shows progression of spectra collected during the first hour of
Aß1-42 oligomeric species production in DMSO+TRIS buffer at 25°C. It is
important to indicate that the predominant species are antiparallel !-sheet and "-
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helix as it can be seen in 32(d); this behavior was also observed in the case
studied in section 4.2.1.1 for Aß1-42 monomers in HFIP (Figure 23(b)).
For the case of 48 hours study, the spectra of the Aß1-42 oligomers (Figure
33(a)) showed some instability as evidenced by the Figure 33(b) and Figure
34(b), not reaching and stable spectra trajectory and reflected on the variability
from time to time. However, this was not an impediment for the oligomeric
structure to form and be stable (Figure 35). The explanation for this movement
among the spectra might be due to the fact that these oligomers are in a reactive
state, therefore the structures and even the adsorption varied from spectrum to
spectrum.
Even as the stability of Aß1-42 oligomers lags behind that of Aß1-40, it is
evident that at all times "-helix and antiparallel ! sheet are the dominant
structures contained and stabilizing the oligomeric species (Figures 34(c) and
(d)) of Aß1-42 peptide. Figures 34(c) and (d) are the result of deconvoluting the
average spectra shown in Figure 34(a).

Figure 33. Amide I and II of Aß1-42 Oligomers during Oligomerization. (a) Spectra
of the amide I and II regions for Aß1-42 in DMSO+PBS during 48 hours of
incubation at 25°C. (b) Spectra selected in 4 hours ranges (red spectra)
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Figure 34. Kinetics of Aß1-42 Oligomers in DMSO+TRIS Solution. (a) Average
spectra obtained from the 4 hours range shown in Figure 33(b). (d) Variances
calculated from 33(b) for the average spectra. (c) Secondary evolution of Aß1-42
in DMSO+TRIS during 48 hour of incubation. (d) Change of secondary structure
content for Aß1-42 in DMSO+TRIS during 48 hour of incubation

74

Figure 35. Morphology of Aß1-42 Oligomers. (a) 1x1-#m x-y scans of Aß1-42 from
0.5h- 48h of incubation. (b) Average diameter of the oligomers encountered in
solution at different incubation times, even when at 12 hour and 24 fibrils are
shown, they are rarely found, this fibrils have diameters in the range of the
oligomeric species (35±10nm)

The progression of AFM scans of Aß1-42 oligomeric species in Figure 35
(a), and the analysis of particle sizes in (b) show changes in size of oligomers
that stabilizes after 24 hours. Even though fibrils were observed in AFM
experiments, these were scarce and did not play an important role in the
morphology of aggregates, which were dominated by Aß1-42 oligomeric species.
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4.2.1.2.3. Oligomers of Aß40/42 Peptide
The study in this section mirrors the two preceding studies but tests a
combination of both peptide Aß1-40 and Aß1-42 at a molar ratio of 1:1. Similarly to
Aß1-40 and Aß1-42 oligomeric study, ATR-FTIR spectroscopy and AFM analysis
were performed for 1 hour and 48 hour time scopes.

Figure 36. Change of Secondary Structures of Aß40/42 Incubated in DMSO and
TRIS at 25°C. (a) Spectra of the Amide I and II regions from 0 to 60 minutes,
Amide II shows protein adsorption, on Amide I region shifting can be observed
noting instabilities; (b) Reorganization of the secondary structure that trigger the
process of oligomers formation; (c) Change in secondary structure present in the
Aß40/42 peptides during the first 60 minutes of incubation in DMSO+TRIS solution
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Figure 36(a) shows the spectra (amide I and II regions) corresponding to
the initial 60 minutes of incubation, (b) shows the decreased and stabilization of
the evolution for antiparallel structures and the rest, respectively. Figure 36(c)
shows that antiparallel ß-sheet structures are dominant in this first hour of
incubation.

Figure 37. Kinetics of Aß40/42 Oligomers in DMSO+TRIS Solution. (a) Spectra of
the Amide I and II regions for Aß40/42 peptide spectra during 48 hours of
incubation at 25°C; (b) Sets of spectra selected each 4 hours (red spectra),
during 0 to 48 hour of incubation

Figure 37(a) shows the spectra collected from 0 to 48 hours of incubation,
representing only the amide I and II regions of the spectrum, (b) explains
schematically the process of time sets selection. The stability spectral analysis
for Aß40/42 oligomers shown in Figure 38 (b) and corresponding to the average
spectra in (a), shows that after 12 hours of incubation the oligomers reach
stability. This can also be visually observed in figure 37(b).
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Figure 38. Kinetics and Change of Secondary Structure Content of Aß40./42
Oligomers Prepared in DMSO+TRIS Solution. (a) Spectra obtained from
averaging the 4 hours range as shown in Figure 37(b); (b) Percentage of
variance calculated for each average spectra in (a) from the data shown in Figure
37(b). (c) Secondary structure evolution of Aß40/42 in DMSO+TRIS during 48 hour
of incubation; (d) Change in secondary structure content for Aß40/42 in
DMSO+TRIS during 48 hour of incubation

During the first 60 minutes of the stability study, the oligomeric equimolar
mixture of Aß40./42 seems to reach relative stable conformations (Figure 36(c)),
after this short initial time, the peptide mixture shows and increase in antiparallel
ß-sheet dominating over the second structure increasing, the parallel ß-sheets.

78

AFM analysis was performed to this peptide combination, finding no
evidence of adsorption to the mica at any time, suggesting that the oligomers in
the ATR crystal are in a dynamic equilibrium of adsorption and desorption,
explaining the adsorption shown in Figure 39, and at the same time the absence
in the mica surface (not shown).

Figure 39. Kinetics of Aß Oligomeric Species Adsorption. The values shown in
this plot are the integrated areas under each amide II region corresponding to
each different time, and as explained in section 3.3.1.2 it corresponds to the
peptide adsorption on the ATR crystal

A comparison of the first 48 hours of oligomeric adsorption values from the
Amide II region in Figure 39 reveals that Aß1-40 has the most adsorption tendency
to the FTIR crystal while Aß1-42 has a comparable adsorption to the peptides
mixture; still Aß40./42 has a value in between the individual peptides.
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4.2.1.3. Fibrillization of Aß Peptides at 25°C
The main focus of this work is to understand and obtain the necessary
knowledge to interpret the mechanisms of peptide fibrillization, to then be able to
target a dissolution process (this will be discuss in Chapters 5 and 6). In the
amyloid hypothesis, it is stated that when an imbalance in the amyloid peptide
production and clearance equilibrium is altered, this drives to Aß plaque
formation [88, 89], initiating a cascade of effects that ultimately lead to neuronal
death, hence understanding the process of peptide aggregation at the molecular
lever is important to treat the disease.
This study parallels the previous sections for monomers and oligomers of
Aß40., Aß42 and the equimolar mixture of Aß40./42. In this set of experiments, the
peptide film dissolved in DMSO was diluted to 100#M with PBS and incubated at
25°C, protocol that yields to fibril formation [72].

4.2.1.3.1 Aß1-40 Fibrils
Aß1-40 fibrils were studied for both time scopes of 60 minutes and up to 96
hours, the samples were analyzed with ATR-FTIR spectroscopy and AFM.
The first 60 minutes of Aß1-40 fibril formation of process have very little
stability as it is evidenced by the changes in spectra shown in Figure 40(a), the
integrated absorbance of the Amide I and Amide II in (b), and absolute and
relative structure content values from (c), and (d).

80

Figure 40. Change of Secondary Structures of Aß1-40 Prepared in DMSO+PBS
Solution and Incubated at 25°C. (a) Spectra of the Amide I and II regions from 0
to 60 minutes, Amide II shows protein adsorption, on Amide I region shifting can
be observed showing the molecular rearranging of the molecules; (b)
Comparison between Amide I and Amide II integrated absorbance from 0 to 60
minutes; (c) Reorganization of the secondary structure that trigger the process of
peptide aggregation; (d) Change of secondary structure content of Aß1-40 in the
first 60 minutes of incubation
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Figure 41. Fibrillization of Aß1-40 in DMSO+PBS. The fibril are formed at 25°C
and monitored during 96 hours. (a) Amide I (1700-1600 cm-1) and amide II (16001500 cm-1) spectra. (b) Amide I region, spectra selection shown up to 48 hours;
this study is performed to evaluate the stability and structural change of the
peptides. (c) Average spectra calculated from the selected times in (b)

The stability analysis presented in Figure 41 allows observing the limited
stability of the fibrils formed by Aß1-40 in PBS until more than 80 hours as average
spectra show in (c); time frame not shown in (b).
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Figure 42. Fibrillization of Aß1-40 and Secondary Structures Change. (a)
Morphological change monitored with AFM. (b) Most relevant secondary
structures kinetics. (c) Most relevant secondary structure content

Figure 42(a) shows the progression of fibril formation for up to 240 hours
for the AFM scans, and 96 hours for FTIR amide I secondary structure content.
The analysis shows that fibrils are stable at more than 80 hours and the
predominant structures are antiparallel !-sheet and "-helix for formed fibrils.

4.2.1.3.2. Aß1-42 Fibrils
Aß42 fibrils were studied under FTIR-ATR and AFM analysis for both time
scopes of 60 minutes and 240 hours, the analyzed data is presented in this
section.
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Figure 43. Change of Secondary Structures of Aß1-42 Prepared in DMSO+PBS
Buffer Solution to 100 #M and Incubated at 25°C. (a) Spectra of the Amide I and
II regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I
region shifting can be observed showing instabilities; (b) Comparison between
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c)
Reorganization of the secondary structure that trigger a process of aggregation
into oligomers is shown; (d) Change of secondary structure content of Aß1-42 in
the first 60 minutes of incubation

Aß1-42 process of fibril formation reaches relative stability at 30 minutes as
it is evidenced by the changes in spectra in Figure 43(a), this is further confirmed

84

by the changes in absorbance of the Amide I and Amide II in (b), and absolute
and relative structure content values from (c), and (d).

Figure 44. Fibrillization of Aß1-42 at 25°C. (a) 0 to 72 hours spectra during the
Aß1-42 peptide aggregation. (b) Aggregation evolution by time ranges. (c)
Averages spectra calculated from (b)

The stability analysis presented in Figure 44 shows the relatively high
stability of the fibrils formed by Aß1-42 in PBS which increases in the 72 hours of
the study, as stability visualization in (b), and as average spectra show in (c).
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Figure 45. Secondary Structure Change during Fibrillization of Aß1-42 at 25°C. (a)
Rate of aggregation per structure. (b) Percentage change of secondary structure
content. (c) AFM morphological characterization of the Aß1-42 fibril formation

Figure 45 shows secondary structure analysis of FTIR-ATR data for up to
96 hours shows that the remaining dominant secondary structure over the long
term evolution of fibrils is parallel !-sheets structure.
The AFM scans on Figure 45(c) show that the morphology of the fibrils
change over the 240h scan which is in agreement with the secondary structure
analysis in Figure 45(b) in which only parallel ß-sheet structure remains dominant
among other secondary structures.
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4.2.1.3.3. Aß40/42 Fibrils
The fibrillation process of Aß1-40 and Aß1-42 at a ratio of 1:1 and at 25°C
was investigated in this section. As for the previous cases, the study was done
for the first hour and then for up to 96 hours.

Figure 46. Change of Secondary Structures of Aß40/42 Dissolved in DMSO after
Diluting with PBS Buffer Solution to 100 #M. (a) Spectra of the Amide I and II
regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I
region shifting can be observed showing instabilities; (b) Comparison between
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c)
Reorganization of the secondary structure that trigger a process of aggregation
into oligomers is shown; (d) Change of secondary structure content of Aß40/42 in
the first 60 minutes of incubation
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Figure 46 shows the first hour evolution of the fibrillization process the
Aß40/42 equimolar mixture, which initially has as dominant secondary structure,
antiparallel !-sheets.

Figure 47. Fibrillization of Aß40/42 at 25°C. (a) 0 to 72 hours spectra during the
Aß1-42 peptide aggregation. (b) Aggregation evolution by time ranges
The stability analysis of the Aß40/42 depicted in Figure 47, shows little
stability of the fibrils during the 72 hour timeframe.
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Figure 48. Fibrillization of Aß40/42 at 25°C. (a) Spectra average by time range, (b)
AFM morphological characterization of the Aß40/42 fibril formation (c) Most
relevant structures changing during fibrillization, (b) Percentage change of most
relevant secondary structures

The morphology of the Aß40/42 fibrils depicted in Figure 48, shows parallel
!-sheets as the dominant structure for most of the process on the long term
analysis.
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Figure 49. Comparing the Morphological Evolution of Aß Peptides during Fibril
Formation at 25°C. (a) AFM morphology characterization. (b) TEM images of Aß
peptides at 10 days of incubation

The AFM scans and TEM images in Figure 49 provide an opportunity to
compare the morphology of fiber formed by either Aß1-40 and Aß1-42 peptide, as
well as their 1:1 combination. AFM scans at 1x1!m reveal that fibrils formed by
the mix of peptides Aß40/42 are generally thicker and formed of globular
aggregates; this is the case for initial fibril structures formed in Aß1-40.
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Figure 50. Morphology of Aß Peptides Films Prepared in DMSO + TRIS and
DMSO + PBS Solution. The Films shown in (a) where obtained 30 minutes after
the samples were prepared. (b) Topographical analysis of oligomers in
DMSO + TRIS solution; (c) Topographical analysis of oligomers in DMSO + PBS
solution
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The observations of morphology about fibrils formed from the peptide
equimolar mixture of Aß40/42 is mirrored by the morphology of oligomeric
aggregates shown in Figure 50(a). Quantification of such aggregates from AFM
scans show that in the case of the TRIS solution, the size of oligomeric
aggregates from Aß1-40 are smaller with smaller average height, Aß1-42 are larger
in size, and the size of oligomers from the mix Aß40/42 appear in between those of
the peptides. This is not the case for oligomeric aggregates in PBS solution
shown in 50(b); which are considerably larger for the mix Aß40/42 than those for
each peptide on their own. This morphological behavior is similar to that shown
for fibrils in Figure 49.

4.2.1.4. Effects of Temperature during the Fibrillization of Aß Peptides
This section introduces two new studies complementary to the Aß
peptides fibrillization assessment. Now, varying the incubation temperature to
37°C. these studies are only performed for Aß1-42 and Aß40/42 peptides.

4.2.1.4.1. Aß1-42 Fibrils
Figure 51 shows the evolution of both amides (I and II) during the process
of fibril formation at 37C. Amide II shows adsorption of protein. Amide I region
shows molecular rearrangement better appreciate it in Figure 51(b). As
previously explained, Figure 51(c) represents the average spectra for the 4 hours
ranges selected from Figure 51(b), and the analysis of secondary structure is
(performed to the amide I region) is shown in Figure 52(a) and (b).
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Figure 51. Aß1-42 Peptide Fibrillization at 37°C. (a) Spectra from 0 to 96 hours of
incubation. (b) Time selection by ranges. (c) Average spectra calculated per
time range selected in (b)
Figure 52(b) shows the parallel structures as the dominant conformation
along with the unordered structures. To assess the effect of temperature on the
evolution of parallel and antiparallel structures, these structures are compared in
Figures 52(c) and (d); it can be observed in these two figures that at 25°C the
fibrillization process is more stable than at 37°C, however they both follow same
path of aggregation. In addition the fibrils encountered at 48 hours of incubation
have similar morphology in both cases (Figure 52(e).)
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Figure 52. Aß1-42 Secondary Structure Change Effects of Temperature during
Fibrillization. (a) Kinetics of the secondary structures at 37C. (b) Content of the
secondary structures change. (c) Temperature effect on the change of parallel ßsheet structures. (d) Temperature effect on the change of antiparallel ß-sheet
structures. (e) Morphology of the Aß40/42 fibrils at 48 hours of incubation
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4.2.4.1.2. Aß40/42 Fibrils
Figure 53(a) shows the evolution of amide I and II for Aß40/42 when the
incubation temperature is 37°C. In Figure 53(b) the changes per 4 hour ranges
of the two amides can be explored, and the averages of the time ranges are
shown in Figure 53(c), the changes in morphology during the aggregation
process is shown in Figure 53(d).

Figure 53. Fibrillization of Aß40/42 at 37°C. (a) AFM morphological
characterization of the Aß40/42 fibril formation. (b) Secondary structure as function
of preferable energetic state during aggregation
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Figure 54. Temperature Effect during the Fibrillization Process of Aß40/42. (a)
Rate of aggregation per structure AFM morphological characterization of the
Aß40/42 fibril formation. (b) Percentage change of secondary structure content. (c)
Temperature effect on the change of parallel ß-sheet structures. (d) Temperature
effect on the change of antiparallel ß-sheet structures

From Figure 53(c), the evolution of secondary structures in the amide I
region was calculated and represented in Figures 54(a) and (b). These graphs
correspond to the change in integrated absorbance and its normalized values
respectively.
Figures 54 (c) and (d) compares the evolution of parallel and antiparallel
ß-sheet structures at 25°C and 37°C; showing that at 37°C the fibrillization takes
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place rapidly (first 12 hours of incubation) when it reaches equilibrium. In
comparison, the fibrillization process at 25°C, the stability of this process is
reached at 40 hours of incubation. In addition Figure 55 shows the morphology
of fibrils, which have similar appearance at 48 hours of incubation.

Figure 55. Comparison between Aß40/42 Fibrils Prepared at 25°C and 37°C.
Images taken at 48hours of incubation with AFM at a scan size of 10x10#m x-y

4.3.

Chapter Remarks
One important finding of this study is that preferentially, fibril formation is

characterized by the increase of parallel ß-sheet structures, while if peptide
species are in solution the preferential secondary structure is antiparallel ß-sheet
configuration.
The experiments and analysis in this chapter allowed the combinatorial
study of two different Aß peptides isoforms Aß1-40, Aß1-42, and their equimolar
mixture, Aß40/42. The peptides were studied under 5 different set of conditions
designed to control in different ways the aggregation of amyloid proteins. The
conditions allowed for the formation of monomers in solution, monomers on a
film, oligomers, fibrils formed at 25°C, and fibrils formed at 37°C. The stability of
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the aggregation process and the dominant secondary structures were assessed
to provide key knowledge in the understanding of the effect of monoclonal
antibodies (mAb) on Aß peptides and their aggregation in later chapters.
The results from this chapter have been summarized in a Table 4, which
allows comparing the different cases from the entire study.

Table 5. Dominant Structures and Stability Table

Aß1-40

Aß1-42

Aß40/42

Monomers HFIP Dominant

HFIP Dominant

HFIP Dominant

25°C

Structures:

Structures:

Structures:

Antiparallel !-sheet

Antiparallel !-sheet

Antiparallel !-sheet

"-Helix
(stable)

(stable)

(stable)

Film Dominant

Film Dominant

Film Dominant

Structures:

Structures:

Structures:

Parallel !-sheets

Parallel !-sheets

Parallel !-sheets

"-Helix

Antiparallel !- sheet

"-Helix

"-Helix
(stable)

(stable)

(stable)

DMSO Dominant

DMSO Dominant

DMSO Dominant

Structures:

Structures:

Structures:

Antiparallel !-sheet

Antiparallel !-sheet

Antiparallel !-sheet

(stable)

(stable)

(stable)

Oligomers

Dominant at 60 min: Dominant at 60 min: Dominant at 60 min:

25°C

Parallel !-sheets

"-Helix

Antiparallel !-sheet

Antiparallel !-sheet

(little stability)

(little stability)
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Antiparallel !-sheet
(unstable)

Table 5. (Continued)

Aß1-40

Aß1-42

Aß40/42

Oligomers

Dominant during 48

Dominant during 48

Dominant during 48

25°C

hours:

hours:

hours:

Parallel !-sheets

"-Helix

Antiparallel !-sheet

Antiparallel !-sheet

Parallel !-sheets

(moderate stability)

(moderate stability)

(stable)
Fibrils

Dominant at 60 min: Dominant at 60 min: Dominant at 60 min:

25°C

No perceived

Parallel !-sheets

dominance

Antiparallel !-sheet

Antiparallel !-sheet

"-Helix
(unstable)

(apparent stability)

(moderate stability)

Dominant during 48

Dominant during 48

Dominant during 48

hours:

hours:

hours:

Antiparallel !-sheet

Parallel !-sheets

Parallel !-sheets

(stable)

(moderate stability)

Dominant during 48

Dominant during 48

hours:

hours:

Parallel !-sheets

Parallel !-sheets

"-Helix
(moderate stability)
Reduced after 48
hours:
Parallel ß-Sheets .
Fibrils
37°C

N/A

Unordered
(moderate stability)
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(moderate stability)

A simple assessment of Aß1-40 and Aß1-42 aggregation in oligomeric and
fibril formation conditions shows how the likelihood of stability of the process
flips. Oligomers of Aß1-40 reach stability much faster than oligomers of Aß1-42
while the opposite is true for the fibrillar species where Aß1-42 reaches stability
considerably faster than fibrils formed by Aß1-40 peptide.
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CHAPTER 5
MONOCLONAL ANTIBODIES MODIFY FIBRILLOGENESIS

The main goal of this study was to elucidate and analyze the deviation
from a typical fibrillization process caused by targeting Aß peptide monomers
and oligomers in solution (before fibrillization occurs) with different anti-Aß
monoclonal antibodies (mAb). In addition to the two isoforms, the equimolar
mixture of the Aß1-40 and Aß1-42 (Aß40/42) was studied. The rationale of this
relates to the idea of having antibodies with different specificities that would
better target the peptide mixture. All the experiments were performed at 37°C
and at a substoichiometric molar ratio of 1 to 1000 (antibody to peptide).

5.1.

Summary
In this chapter, the effects of antibodies were studied at a condition close

physiological conditions in the brain. For this, temperature was kept constant at
37°C, and solutions were kept at pH 7.4. A 1:1000 antibody to peptide molar
ratio was chosen to approximate therapeutic conditions. The antibodies were
applied to monomers and oligomers in solution (with exception of the first study
using 6E10 and 2H6 on preformed fibrils) at the initial stage of the Aß40/42
fibrillization process.
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It is worth mentioning, that the oligomeric species of Aß peptide is
recognized by different groups as the toxic specie from the aggregation process,
due to its reactivity [15, 17-20, 87, 90-92], suggesting this species as a possible
effective target for the antibody application.
Table 6 describes the specificity for the monoclonal antibodies tested in
this study. Briefly, 6E10 can bind to the N-terminus of either Aß1-40 or Aß1-42
peptide, 2H6 binds to the C-terminus of Aß1-40 ; 4G8 binds to the mid domain (1724) of either Aß1-40 or Aß1-42; and finally mIgG2b with not specificity to neither
Aß1-40 or Aß1-42 peptides, that is used as a control antibody.

Table 6. Specificity and Binding of Antibodies Tested
Antibody

Specificity

Binding

6E10

n-term 1-16

Aß 1-x

2H6*

c-term 35-40

40 only

4G8 (Signet Dedham, MA)

mid-domain 17-24

Aß 17-x

mIgG2b*3

Control antibody

does not bind Aß species

* Antibodies provided by Rinat-Pfizer

All the antibodies tested were provided either by David Morgan’s group
(USF Health Byrd Alzheimer’s Institute) or Rinat-Pfizer (San Francisco, CA)
directly.

3

Antibody raised against a pseudomonas aeruginosa antigen.
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5.2.

Protocols and Methods
ATR-FTIR, AFM, and TEM analytical techniques were used in the same

capacity as described in previous chapters. Moreover, some of the experiments
with antibodies were also characterized using Western Blot.

5.2.1. Antibody-Peptide Solution
An equimolar mixture of Aß1-40 and Aß1-42 (Aß40/42) was first prepared as
explained in section 4.1.4. In brief, Aß1-40 and Aß1-42 peptides were prepared
separately. Each peptide’s film was redissolved with DMSO and diluted to
100 #M with 0.01 M PBS. These two solutions were then combined in a 1 to 1
molar ratio stock solution.
Amyloid peptides were incubated with each antibody from the beginning of
the fibril formation process. However, 6E10 and 2H6 antibodies were also tested
against 5 days preformed fibrils.

5.2.1.1. Effects of Low Antibody Concentration on Aß40/42 Fibrils
Amyloid-ß peptide fibrils were prepared following the protocol described in
5.2.1. The Aß40/42 solution at 100 #M was aliquoted in three portions; one aliquot
was injected in the ATR-FTIR flow cell, where the aggregation was monitored
over time; the second portion was subdivided in different vials, each
corresponding to different incubation times, later analyzed by AFM and TEM. The
third portion was incubated for later addition of antibody (at day 5) and analyzed
by AFM and TEM at different time over 5 days after antibody addition. Hence, the
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processes of fibril formation and antibody addition were verified with ATR-FTIR
spectroscopy, AFM and TEM. The antibody was added in a molar ratio of 1 to
1000, antibody to peptide, all the samples were incubated at 37°C.
The control solution for this study was the equimolar mixture of Aß40/42
peptides incubated with no addition of antibody for a period of 10 days at 37°C.

5.2.1.2. Targeting Aß40/42 Monomers and Oligomers with Low Concentration
of Different Monoclonal Antibodies
As in section 5.2.1.1, each solution was prepared using a 1:1000
substoichiometric molar ratio, antibody to amyloid peptide respectively. As
described previously, the peptide’s film was first redissolved with DMSO (0.2
mM) and diluted to 100 #M in 0.01 M PBS (pH 7.4), Aß1-40 and Aß1-42 peptides
were prepared separately and then the solutions were combined in a 1 to 1 molar
ratio. Immediately after combining the two peptide solutions the antibody was
added to the peptide’s mixture in a molar ratio 1:1000 of antibody to peptide.
The solution antibody-peptide was divided in two portions each incubated
at 37°C. The first portion of this solution was injected in the ATR-FTIR flow cell
accessory where it was monitored over 10 days of incubation (by spectroscopy).
The other portion of the antibody-peptide solution was subdivided for AFM, TEM,
and Western Blot analysis. Samples were collected over a period of 10 days.
The control for this study was a solution of Aß40/42 peptide prepared with
an antibody (mIgG2b) with not specificity to either peptide.
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In addition to the control above, and to prove that our results correspond
to the antibody-peptide interaction rather than the single antibody and peptide
contribution, a predicted model of secondary structures was calculated, this by
mathematical adding the secondary structures calculated for Aß40/42 peptide
incubated without antibody and the secondary structures of antibodies 2H6 and
6E10 when incubated alone over the same period of time. This is Aß40/42 + 2H6
and Aß40/42 + 6E10. The Aß40/42, 2H6, and 6E10 controls were solutions prepared
and incubated as if they were combined in a 1:1000 antibody to peptide system.
The antibodies used for these experiments (see Table 6) were received
from the provider dissolved in PBS solution at variable concentrations (1-2
mg/ml), hence calculations of the appropriate volume of antibody were performed
to assure the same molar ratio for all experiments. In order to avoid antibody
contamination and unnecessary freeze-unfreeze cycles, all the antibody stock
solutions were aliquoted (in 5 portions) and kept at -20°C once received from the
provider. Prior to use, 1 of the 5 vials containing the antibody was retrieved from
the freezer and allowed to equilibrate to 25°C.

5.2.2. AFM and TEM Characterization
AFM and TEM assisted to determine the state of aggregation of the
peptides in contact with antibodies. In the initial state of aggregation, the peptide
tends to spread fairly uniformly across the substrate where it is deposited.
However, as the incubation time increases, and peptides aggregate into
fibrils, it becomes challenging for the nanoscale-size tip of the AFM to depict
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where fibrils are located on the substrate. At this point, it is better to combine
TEM with AFM to determine the aggregation state and to examine the sample’s
surface distribution. Therefore, some results illustrating the morphology and/or
topology of the samples will be shown with both techniques (TEM adapted to the
AFM scale).

5.2.3. ATR-FTIR Analysis
The background solution used for these studies was the solvent in which
the peptides/antibody systems were prepared, that was 2% DMSO to 98% 0.01M
PBS (v/v). Therefore, all the collected spectra represent the changes of
secondary structures of the antibody-peptide mixture.

5.2.4. SDS-PAGE and Western Blot Analysis
SDS-PAGE and immunoblotting was performed as described by Dahlgren
et al., 2002 [19]. Briefly, individual aliquots of the stock solution collected at the
testing times were centrifuged at 14,000g for 10 min at 4°C in order to remove
large aggregates such as potential fibrils in the supernatant. Iced cold Millipore
water was used to dilute the monomer- and oligomer-containing A!40/42 (or mAbAß mixture) supernatant at 1:5 ratio and mixed with a buffer. Note that there is no
heating nor use of additional reducing agents. These sample were then
combined with a 12 % Bis-Tris NuPage gel using MES as the running buffer
(Invitrogen, US). See Blue pre-stained molecular mass markers were run on
each gel (Invitrogen, US). Peptides separated at 160 V for 1 h and subsequently
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transferred to 0.22 mm PVDF membranes at 35 V for 1hr. The membranes were
blocked for 1 hour at room temperature (RT) using 5 % non-fat dry milk
(International, Diagnostics Group, UK) in 20 mmol/LTris-buffer, pH 7.6, with 137
mmol/L NaCl and 0.05 % (w/v) Tween 20. Subsequently, the membranes were
incubated with a primary antibody in blocking buffer overnight at 4°C. The
primary antibody 6E10 (a mouse monoclonal antibody directed against the
human A! amino acid residues 1-17) was used at a dilution of 1:1000. The
membrane was then rinsed in Tris-buffer, pH 7.6, 137 mmol/L NaCl and 0.05 %
(w/v) Tween 20 three times and incubated with secondary antibody solution of
HRP-labeled rabbit antibodies against mouse IgG (diluted 1:2000) for 1 h at RT.
Rinsing with 20 mmol/L Tris-buffer, pH 7.6, with 137 mmol/L NaCl and 0.05 %
(w/v) Tween 20 was applied again.
Immunostained peptides were visualized using chemiluminescence, in
accordance with the manufacturer’s recommendations (ECL, Amersham,
Denmark). Western blots were scanned using a Fujifilm Lass 300 Intelligent dark
box scanner, and band density of each blot was quantified within linear range of
detection using AlphaEase software.
This immunnochemical analysis was used to monitor the presence of
monomers and oligomers during the aggregation process.
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5.3.

Results, Analysis and Discussions
The outline for subsequent sections is as follows: 5.3.1. the effects of

6E10 and 2H6 antibodies on Aß40/42 pre-formed fibrils (at 5 days of incubation)
are compared; 5.3.2. the effects 6E10 and 2H6 antibodies added at the
beginning of the aggregation process (when only monomers and oligomers are
present) are compared; and 5.3.3. the effects of 2H6, 6E10, and 4G8 antibodies
are compared against mIgG2b, a non-specific antibody.

5.3.1. Effects of Antibodies on Species of Aß40/42 Targeting the Peptides
C-Terminus or N-Terminus
In this section, it is first shown the effects of 6E10 and 2H6 antibodies on
fibrils pre-incubated for 5 days, testing a molar ratio of 1:1000 (antibody to
peptide). Then, these same antibodies were tested against an initial aggregation
stage solution, were mainly oligomers and monomer were present.
The rationale for comparing the effect of antibodies against fibrils or
monomers+oligomers is to determine which species are more likely to be
influenced by the addition of antibodies. It is desired that if an antibody is going to
be used in passive immunization, it should be able to break preformed fibrils or to
stop or prevent their aggregation in the first place. The effect of the antibodies in
this study has been measured depending on how effective they are to induce
antiparallel beta sheet structures or to decrease parallel beta sheets structures
(those structures were associated with monomeric and fibril species,
respectively, in Chapter 4).
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5.3.1.1. Effects of 6E10 and 2H6 on Aß40/42 Pre-Formed Fibrils
As explained in previous sections, an equimolar mixture of Aß40/42
peptides was used to form fibrils, and a substoichiometric molar ratio of 1:1000,
antibody (either 6E10 or 2H6) to peptide respectively was used. Figures 56 (a)(c) show the spectral evolution for amide I and II bands with respect to incubation
time for the control system (Aß40/42 peptides mixture), the Aß40/42 + 6E10 antibody
and the Aß40/42 + 2H6 antibody, respectively. These average spectra were
obtained as described in the Chapter 3 (Section 3.3.1.3). Briefly, continuous
spectra corresponding to a selected time range were averaged into a single
spectrum.
As described above, at day 5, the antibody was added to a preformed fibril
solution, indicated with an arrow (! +mAb) in the spectrum for the control
(Aß40/42) peptide solution (Figure 56(a)). It is worth mentioning that the
background spectrum for Figures 56(b) and (c) was obtained from the control
system at day five of incubation (e.g., prior to adding the antibodies). Moreover,
the Amide II band progression in Figure 55 shows a significant increase for the
case when 6E10 antibody was added (Figure 56(b)). This means that 6E10
antibody promoted surface adsorption of the peptides to the surface. This same
band did not increase, and if anything, it shows a slight decrease when 2H6
antibody was added (Figure 56(c)). This implies that the preformed fibrils did not
necessarily detach from the surface completely. Rather, it indicates that the fibrils
attached to the surface were attacked by 2H6 antibody.
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Figure 56. Influence of Low Concentration Antibodies Targeting Aß40/42 Fibrils.
Average spectra obtained at 37°C, amide I and II regions are shown for (a) the
control mixture of Aß40/42 peptides, (b) 6E10 antibody added to Aß40/42 peptide
mixture (1:1000). This antibody targets the N-terminus of both peptides, (c) 2H6
antibody added to Aß40/42 peptide mixture (1:1000)., antibody with affinity to the
C-terminus of Aß1-40 peptide only. The arrow shown in the spectrum for the
control system at day 5 represents the point where antibodies were added to the
peptide solution

Figure 57 shows the most dominant secondary structures after the amide I
region was deconvoluted for the control and the two cases of the antibody to
peptide systems. Only parallel and antiparallel beta sheet structures are shown
because these two structures provide the most relevant information regarding
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any dissolution effect on the preformed peptides fibrils. Figure 57(a) shows that
in the control system, parallel beta sheet structures increase continuously until
they reach a plateau, which is when saturation has been reached after 48 h of
incubation. Conversely, the progression for the peptide mixture +2H6 shows a
peak with a maximum value at approximately 4 days of incubation in the parallel
ß-sheet structures. Then, there is an abrupt decay of such structures, which
implies that the antibody was able to render conformational changes tied to
dissolution effects (Figure 57(a)). In the case of peptide mixture +6E10, the effect
is better depicted in Figure 57(b), where the parallel beta sheet structures
decreased to less than 5% of total structure content after day 3.
Figure 57(d) shows the appearance of the fibrils found in the three
samples after 10 days of incubation. It is observed that fibrils are still found in the
case of 2H6 addition, but the morphology differs from the control system. That is,
the fibril density is lower and fibril bundles are thinner than fibrils in the control
picture (Top scan compare to bottom scan). In the case of 6E10, fibrils appear to
be spread on the surface, but more abundant in comparison to the control
system (+6E10 TEM Scan in Figure 57(d)).
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Figure 57. Secondary Structure and Morphological Changes of Aß40/42 Fibrils
after Combined with 6E10 or 2H6 Antibodies. Analysis of the secondary
structures performed from the spectra shown in Figure 56.The values of the
control (labeled as Aß40/42) peptides represent the change after the 5 days of
incubation. The peptide mixture and the peptide mixture +antibody were further
incubated for 10 days. (a) Comparison of the kinetics of parallel ß-sheet
structures between the control and the peptide mixtures affected by 2H6 and
6E10 antibodies in a molar ratio 1:1000. (b) Comparison of the parallel ß-sheets
content for all three systems described above. (c) Comparison of the antiparallel
ß-sheet structures content with respect to incubation time for the systems
described above.(d) TEM scans of the control after a total of 15 days of
incubation at 37°C (Top), peptide mixture+6E10 (Middle), and peptide
mixture+2H6 (Bottom). Both systems with the antibodies added were incubated
for 10 days at 37°C
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5.3.1.2. Effects of 6E10 and 2H6 on Aß40/42 Monomers and Oligomers
The study on preformed fibrils on the previous section allows the
statement that the effect of antibodies is limited on preformed fibrils. Continuing
with this study, the effects taking place when antibodies are added at the initial
stage of aggregation are presented.
Figure 58 show the average spectra comparing the amide I and II regions
of the control (Aß40/42), and Aß40/42 peptide treated with eider 6E10 or 2H6
antibodies. The main differences are in the amide I region for the peptide
mixture+2H6 antibody, where most of the secondary structures undergo sudden
transformations at day three of incubation (Figure 59a and (b)). This implies that
the fibril formation is dramatically disrupted. On the other hand, the amide II
region shows significant growth. This increase in the peptide adsorption is
expected since peptide structures undergoing conformational changes may not
be able to go back into solution because they have been corrupted (Figure 58c).
This finding is verified by analyzing the deconvolution of the spectra and the
anatomic morphology of these spectra shown in Figures 59(a), (c) and (d), where
the parallel beta sheet structures decrease, antiparallel beta sheet structures
increase, and surface globular aggregates appear instead of fibrils. Note that
even though antiparallel beta sheets content increased, peptide aggregation on
the surface was relatively high. As for the case of having peptide mixture+6E10
antibodies, the Amide I and II regions follow the control system behavior (Figure
58(b) and Figure 59(a)-(c)). Therefore, this antibody was unable to prevent the
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fibrillization process under these conditions and did not prevent peptide
adsorption to the surface since Figure 59d shows that fibrils were still formed.

Figure 58. Monitoring Aß40/42 Fibrillization Process from the Beginning of the
Incubation Process with N-Terminus and C-Terminus Antibodies. Spectra were
collected at 37°C. Amides I and II changes for (a) Aß40/42 control system (b) 6E10
added to the beginning of the incubation process ofAß40/42 peptides (1:1000
molar ratio). This antibody targets the N-term of both Aß40 and Aß42 peptides. (c)
2H6 antibody incubated with Aß40/42 peptides. 2H6 is affined to the C-term of the
Aß1-40 peptide
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Figure 59. Effects of 2H6 and 6E10 Antibodies on Aß40/42 Monomers +
Oligomers. (a) Compares the parallel ß-Sheet structures evolution for the control
system and for when antibodies where added to the peptide mixture, (b)
Compares the parallel ß-sheets content, (c) Compares the antiparallel ß-sheet
content , (d) AFM images representing the morphology of the fibrils immediately
after antibody addition and after 10 days of incubation for the control system
(Top), and for the aggregates formed with 6E10 (mid) and +2H6 (Bottom)
addition

In order to investigate the changes in the initial species of the fibrillization
process, that is, monomeric and oligomeric species, Western Blot analysis was
also done to these samples. Results are shown in Figure 60. Figure 60(a) shows
the results from Western Blot analysis performed on samples at the same
conditions as in Figure 58. That is, Aß40/42 (control), Aß40/42 + 6E10, and Aß40/42 +
2H6. Figure 59(b) shows the AlphaEase analysis of the soluble species
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(monomers, low molecular weight (LMW) oligomers, and high molecular weight
(HMW) oligomers). Note that monomers and oligomers disappear from the
solution after day 2 for all three cases. This indicates that during the incubation
process, fibrillization is forced and monomeric as well as oligomeric species
undergo configurational changes into much higher molecular weight structures,
which are transparent to/undetected by this technique (fibril aggregates).
However, the HMW oligomeric species abruptly increases after day 3 for the
case of Aß40/42 peptide mixture treated with 2H6 antibody. This means that the
antibody was able to reverse the production of fibril aggregates and induce the
production of oligomers. Conversely, the control system and the samples treated
with 6E10 antibody show that monomers and oligomers disappear and this
antibody is not able to reverse this action. These results obtained with Western
Blot are in line with the data from ATR-FTIR spectroscopy and AFM/TEM
topological studies as depicted in Figures 58 and 59.
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Figure 60. Effect of 2H6 and 6E10 on Soluble Species of Aß40/42 Peptide
Equimolar Mixture during Fibrillogenesis. (a) Western Blot of the control
system(Aß40/42 ), Aß40/42 + 6E10 antibody, and Aß40/42 + 2H6 antibody.

(b)

AlphaEase analysis of soluble species for Monomers (Right), low molecular
weight (LMW) oligomers (Middle), and high molecular weight (HMW)
oligomers(Left)

5.3.2. Proving Suitability of Results
Before continuing with this study, it is necessary to prove that the results
obtained correspond to the antibody-peptide interaction rather than to a pure
contribution of antibody of peptide separately.
For this, different control solutions were ran over 10 days and analyzed.
The control solutions were, Aß40/42 with no antibody addition, antibody 6E10,
and antibody 2H6. In order to prove the results presented here, the secondary
structures corresponding to peptide + 2H6, peptide + 6E10, and peptide +
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average of 6E10 and 2H6 were mathematically added. The results show (Figure
61) that when comparing to the experimental data, the secondary structure
kinetics is completely different from the predicted values. Thus depicting
completely different behaviors.

Figure 61. Comparison of Predicted Secondary Structures vs. Experimental
Structures. (a) Predicted behavior for the average values of antibodies control
6E10 and 2H6 when added to Aß40/42 control. (b) Predicted behavior for the
average values of antibodies control 6E10 when added to Aß40/42 control. (c)
Predicted behavior for the average values of antibodies control 2H6 when added
to Aß40/42 control. (d) Experimental values for 6E10: Aß40/42 at 1:1000. Control. (e)
Experimental values for 2H6: Aß40/42 at 1:1000.
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This study proves that when any antibody (that binds the peptide) is added
to the peptide mixture, the resulting spectra correspond to the interaction
antibody-peptide in solution, and not to the independent spectra. Hence, our
results show a fair representation of the effect of antibodies on amyloid beta
peptides during fibril formation or disruption.

5.3.3. Effects of Antibodies on Aß40/42 Monomers and Oligomers
This study compares the effects of antibodies on an initial system mainly
composed by monomers and oligomers in solution. The study compares three
antibodies that bind either or both peptide against a non specific antibody.
The results in Figure 62 show the existence and increase of a peak
centered in the parallel ß-sheet frequency region (1630cm-1) for the cases of the
control, peptide treated with 6E10 and peptide treated with 4G8, when in
comparison to the peptide treated with 2H6 this peak seems to decrease and
with the shifting of peaks in other regions. Once Figures 62(a)-(d) are
deconvoluted and integrated, the comparison can have greater detail as shown
in Figure 63(a)-(c), proving that from all the antibodies only when the peptide is
treated with antibody 2H6, there is a noticeable decrease in parallel ß-sheets and
an increase in antiparallel ß-sheets structures after day 3 of incubation.
In addition, Figure 63(d) compares the morphological appearance of the
four systems under study, showing the formation of fibrils in the system of
peptide treated with IgG2b, 6E10, and 4G8, when in the case of peptide treated
with 2H6 amorphous aggregates are found rather than fibrils.
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Figure 62. Monitoring Aß40/42 Fibrillization Process from the Beginning of the
Incubation Process with N-Terminus and C-Terminus Antibodies. Spectra were
collected at 37°C. Amides I and II changes for (a) Aß40/42 control system (b) 6E10
added to the beginning of the incubation process ofAß40/42 peptides (1:1000
molar ratio). This antibody targets the N-term of both Aß40 and Aß42 peptides. (c)
2H6 antibody incubated with Aß40/42 peptides. 2H6 is specific to the C-term of the
Aß1-40 peptide. (d) 4G8 antibody incubated with Aß40/42 peptides. 4G8 has
specificity to the mid domain of both Aß1-40 and Aß1-42 peptide.
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Figure 63. Effects of 2H6, 6E10, and 4G8 Antibodies on Aß40/42 Monomers+
Oligomers. (a) Compares the parallel ß-Sheet structures evolution for the control
system and for when antibodies where added to the peptide mixture, (b)
Compares the parallel ß-sheets content , (c) Compares the antiparallel ß-sheet
content , (d) AFM images representing the morphology of the fibrils immediately
after antibody addition and after 10 days of incubation for the control system
(Top), and for the aggregates formed with 6E10, 4G8, and 2H6 (Bottom)
addition.

This study proves that it is possible to discern and evaluate the effect of
antibodies by analyzing the content and evolution of secondary structures of the
system, and that this results can be corroborated by the physical characterization
of the sample using AFM and TEM.
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5.4.

Chapter Remarks
The experiments in this chapter tested various monoclonal antibodies with

different specificity against Aß peptides. Aß1-40 and Aß1-42 peptides were ratio in
a molar mixture of 1 to 1, and for every case, the antibody to peptide molar ratio
was 1 to 1000.
2H6 antibody targeting the C-terminus of Aß1-40 decreased the content of
parallel !-sheets and increased the content of antiparallel !-sheets, these results
are summarized in Table 6. The rise in the content of antiparallel !-sheets might
indicate the presence of unstable Aß40/42 oligomeric species (Chapter 4, Table 5).
The effectiveness of the evaluation methods was tested as a platform to
evaluate the effects of antibodies used against amyloid peptides.
In general, the use of antibodies to target Amyloid Beta during the
fibrillization process seems to be more effective that targeting fully formed fibrils.
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Table 7. Summary of Observations for the Antibodies Tested in this Chapter
Antibody

Specificity

Observable Effect

6E10

Aß1-40 and Aß1-42

• No effect to preformed fibrils

n-terminus (1-16)
2H6

Aß1/40

• No effect on secondary structure content
• No effect on fibrillization process
• Decrease Parallel !-sheet content (both on
preformed and in fibrillization)

c-terminus (35-40)

• Increase antiparallel !-sheet content (only in
fibrillization)
• Limited Effect on preformed fibers
• Stopped fibrillization only allowing oligomers

4G8

Aß1/40 and Aß1/42
Mid-domain (17-24)

mIgG2b

Non-specific

• No effect on secondary structure content
• Stopped fibrillization only allowing oligomers
• No effect on secondary structure content
• No effect on fibrillization process
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CHAPTER 6
MIMICKING THE NEURON MEMBRANE SURFACE

6.1.

Lipid Bilayer Membranes and their Relevance to Aß Plaque

Formation
Lipid bilayer membranes are an important element of living cells,
supported by a network of structural proteins called the cytoskeleton. An
important characteristic of lipid bilayer membranes is their natural fluidity, which
allows free movement of lipid molecules on their own monolayer. This fluidity
shows differences throughout the cell membrane, and varies depending on the
composition of the principal molecules forming the lipid bilayer: phospholipids,
cholesterol, and glycolipids. The biophysical characteristics of the lipid
membrane also allow certain proteins to embed and anchor or penetrate through
them.
The Alzheimer’s disease A!-hallmark supposes the formation of
extracellular A! plaques; these plaques are formed on the cell membrane by
binding to membrane molecules and by partial insertion into the cell membrane.
It is evident that altering the homeostasis of membrane components such as
cholesterol, leads to accelerated plaque formation that might be related to the
anchoring or the release of A! [93]. Besides the biological implications, the
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biophysical role of higher cell membrane contents of cholesterol and other
intramembrane components is yet not well understood. However, recent studies
suggest that cholesterol and membrane rigidity might hinder A! penetration
resulting in amyloid accumulation on cell membranes [94].
This chapter presents two methods for building in vitro lipid bilayers with
the potential to be used as a platform for studying biophysical phenomena
related to A! plaque formation on lipid bilayer membranes. Two techniques for
creating lipid bilayers were explored: Langmuir-Blodgett deposition technique
and self-assembled bilayer membranes from lipid vesicles. In both cases, the
lipid bilayer membranes were deposited on a thin film of polyethylene glycol
(PEG), which acts as a cushion layer to the lipid bilayers and serves to mimic
membrane fluidity [95].
The composition of model in vitro membranes can be made to mimic
different conditions important to the understanding of A! plaque formation by
reproducing in a monolithic way local characteristics of membrane domains. One
of the challenges encountered in reproducing cell membrane characteristics in
vitro lipid bilayer is reproducing membrane fluidity; this can be overcome by using
a cushion layer below the in vitro lipid membrane.

6.2.

Soft-Support Layer Using Polyethylene Glycol
Polyethylene glycol (PEG) is an amphiphilic oligomer used to build the

soft-supported layer. PEG is a linear or branched neutral polyether that is soluble
in water and most organic solvents. The following is the chemical formula for
125

PEG: HO-(CH2CH2O)n-CH2CHOH. PEG is utilized in this study because its
physicochemical properties allow its use as a cushion substrate or coating
polymer, and it has been a part of previous studies by our group [96]. When in
aqueous solution, PEG rejects other polymers and proteins, and can form twophase systems with other polymers. This property is based on its molecular
conformation in aqueous solution, whereby PEG exposes uncharged hydrophilic
groups and shows very high surface mobility (steric exclusion).
PEG can also be used to coat surfaces with very little chemistry
modification to these surfaces. When surfaces are coated with PEG, they
become hydrophilic and protein rejecting. This protein-rejecting characteristic of
PEG makes it of value as a cushion layer under a lipid bilayer, as it would reduce
the probability of proteins adhering to the substrate underneath the lipid bilayer
membrane. Additionally, when chemically attached to a substrate, PEG
maintains its biological and biocompatible properties. For all these reasons, PEG
is an attractive substrate for using it as a support or cushion layer to increase in
vitro fluidity of lipid bilayer membranes.

6.2.1. Construction of the Soft-Support Layer Using PEG
Following a protocol developed by Alcantar et al. in 2000 [97], a polished
glass surface (rectangular hemacytometer cover glass, 12-519-10, Fisher Sci)
was activated by submerging it in a 10 % w/v sodium hydroxide (NaOH, 1310-732, Acros Organics) solution and sonicating (Model FS30, Fisher Sci.) it for 5
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minutes. During the surface activation of polished glass, silanol groups (Si-OH)
are produced at the solid-air interface (Figure 64).
The glass was retrieved from the NaOH solution and cleaned by rinsing it
multiple times with Millipore water. Ultrapure nitrogen was then applied to
remove any water traces until the surface was completely dry. The activated
glass surface was then submerged in the polyethylene glycol (PEG, 400 Da,
P3265-500G, Sigma) for one hour at 100°C. This resulted in the PEG being
grafted to the surface of the activated polished glass (Figure 64.b). This process
occurs through a reaction between the end alcohol groups of the PEG molecules
with the Si-OH molecules on the activated glass (Figures 64.a and 64.b).

(a)

(b)

Figure 64. PEG Cushion Layer Construction. (a) During the surface activation
of polished glass, silanol groups (Si-OH) are produced at the solid-air interface.
(b) Schematic of the PEG surface grafting reaction, where silanol groups on
the surface of the activated polished glass lose the hydrogen and forms water
with the end hydroxyl group of the PEG molecules. This result in the PEG
being grafted to the surface of the activated polished glass.
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The PEG grafted glass was retrieved from the PEG solution while still hot
and immediately rinsed avoiding direct contact with the water flow. Finally, the
surface was dried by gently exposing it to a flow of ultrapure nitrogen.

6.3.

Lipid Bilayer Construction Techniques

6.3.1. Langmuir-Blodgett Deposition Technique
This technique is used to deposit multiple organized and compact layers,
one monolayer at a time. Any organic or inorganic molecule of amphiphilic nature
can be deposited [98, 99]. Typically, a bed of water is used as the initial surface
for deposition (subphase) in which the molecules to be deposited are gently
placed. For this, a suitable solvent with lower density than the subphase (and
with high vapor pressure) is used to dissolve the molecules. This solvent is
easily evaporable leaving a monolayer of the molecule of interest on the water’s
surface.
Once a monolayer of the molecule is formed on the subphase, the
deposition takes place by slowly pulling out a previously submerged substrate,
where the monolayers will be deposited in an upward followed by a downward
direction. These movements are perpendicular to the subphase surface (Figure
65.a).
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This technique is extremely simple and allows deposition of a single layer,
bilayers, or multiple layers one at a time. Depending on the orientation of the
amphiphilic molecule layers with respect to the substrate and to each other, the
deposition can take one of three forms: X-type, Y-type, or Z-type (Figure 65.b).

Figure 65. Langmuir-Blodgett Deposition Technique. (a) Schematic of the
deposition methodology. (b) Types of deposition based on the order of layers.

The Langmuir-Blodgett (LB) trough (Figure 66) requires an environment
completely free of contamination to avoid particles clinging to the surface. These
particles can contaminate and perturb the deposition quality. The trough is
located inside a laminar flow cabinet to avoid potential contamination. However,
the airflow is turned off during lipid deposition in order to protect the trough from
the environment. When necessary, Millipore water and sometimes organic
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solvents (for instance: chloroform) are used to clean the trough. A common
indicator of cleanliness is the absence of air bubble formation. The presence of
bubbles with the addition of water indicates potential contamination. Hence,
bubbles are eliminated by suction.

Figure 66. Langmuir-Blodgett Trough. The principal components of the
trough are highlighted in this photo.

The LB trough is connected to a computer system, and is run by software
that allows the control of parameters such as surface area, superficial tension,
and substrate deepness necessary for the actual deposition. The area,
deposition pressure, and lipid concentration used for the depositions are chosen
based on calibration experiments that are run beforehand and are a function of
the lipid’s nature.
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6.3.1.1. Layer-by-Layer Lipid Membrane Construction
Lipid bilayers composed of 1,2-Distearoyl-sn-Glycero-3
Phosphoethanolamine (DSPE, 850715X, Avanti Polar Lipids Inc.) were deposited
onto the grafted PEG layer using the Langmuir-Blodgett deposition technique (LB
trough, Model 611D, Nima Technology) as explained earlier in this chapter. The
polished glass surfaces containing the soft-supported PEG layer were kept inside
of a laminar flow cabinet (Class 100) to minimize contamination.
The initial uncompressed surface area was fixed at 300 cm2. The lipids
were compressed using a LB barrier speed of 25 cm2/min. The parameters used
for this experiment, such as area, deposition pressure, and lipid concentration,
were developed in a previous study [100]. A volume of 100 #L of DSPE was
dissolved in chloroform (HPLC grade, 67-66-3, Acros Chemicals) at a
concentration of 15 #g/#L. This solution was gently poured on the air/water
interface using a gas tight Hamilton syringe (allowing 5 minutes for the solvent to
evaporate). During the process of deposition, the surface pressure was kept
constant at 30 mN/m. The process of deposition of the first lipid monolayer took
place by dipping the activated polished glass with the PEG layer at a velocity of 2
cm/min; the second lipid layer is deposited when the dipping motion is reversed,
removing the glass from the trough and placed in a fluid reservoir for
transportation (Figure 67).
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Figure 67. Schematic of Lipid Bilayer Construction. (a) Schematic of first lipid
monolayer deposited on the cushioned layer (PEG). (b) Representation of the
soft-supported lipid bilayer. Hydrophilic and hydrophobic domains are shown c.
A double layer of lipid is deposited on top of the PEG layer using LangmuirBlodgett deposition technique.

6.3.1.2. Soft-Supported Lipid Bilayer Characterization: Surface Topography
Atomic Force Microscopy (AFM, MFP-3D, Asylum Research, Santa
Barbara, CA) was used to physically characterize the surface
topography/topology of the soft-supported lipid bilayer membranes. Tapping
mode was used to scan the surfaces, which were at all times submerged in
deionized water to preserve the integrity of the lipid bilayer. The cantilevers used
had typical spring constant < 1 N/m. Scan sizes were 10x10 #m. (Figure 68).
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Figure 68. Characterization of Soft-Supported Lipid Bilayer Membrane.
(a) RMSR change at different steps of construction. (b) AFM images (0.5x0.5#m x-y scan size) at the different steps of the lipid bilayer assembly

The lipid bilayer membranes were kept in contact with saturated lipid
solution at all times to avoid air exposition, which could consequently cause
damage to the samples.
While LB is a simple and very reliable technique that allows deposition of
homogenous monolayers, there are some limitations to this technique. First, the
substrate geometry has to be open and flat, second, the size of the substrate
cannot be greater than 4 cm x 4 cm, and third, the transfer from the LB-trough
(where the deposition takes place) to a container is difficult because any
exposure of the bilayer to the air would destroy it. This makes it difficult to store
and unsuitable for certain characterization techniques (like closed ATR-FTIR flow
cell). Therefore, other methods to construct lipid bilayers must be considered, as
is the case of vesicle based self-assembled lipid bilayers.
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6.3.2. Vesicle Based Self-Assembled Lipid Bilayers
Vesicle self-assembly technique provides an attractive alternative to
overcome the limitations of the LB lipid deposition technique, such as size and
geometry of the starting substrate, and difficult handling.
The process consists of the spontaneous fusion of small unilamellar
vesicles [101] onto a surface substrate. Vesicles are made of lipid aggregations
when they are forced to associate in cores as micelles for instance (unilamellar)
at controlled media conditions.
A general methodology is to dissolve the lipids in a solvent, i.e.
chloroform, and then, the lipid in suspension is placed in a rounded flask. The
solvent is left to evaporate overnight and vacuum for 4 hours before further
preparation. Once the film is completely dry, water is used to hydrate the film by
heating and gently agitating it; once the transition temperature of the lipid is
overcome the lipid will completely be dissolved. The last step in the preparation
of vesicles is to slowly cool down the solution allowing the lipids to organize,
resulting in vesicles formation. The deposition by self assembly technique, is
accomplished by the interaction between the prepared vesicles and the treated
surface substrate. This interaction burst the vesicles and drives a self-assembled
lipid bilayer formation.

6.3.2.1. Self-Assembled Lipid Bilayers from Vesicles
As a second stage of this study, the formation of lipid bilayer membranes
by self-assembly technique was performed.
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Lipid bilayers were prepared with the same lipid used in the Section
6.3.1.1.: 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE). Following
the principles explained in the previous section, for this study the vesicles were
prepared by using 2 mg of lipids dissolved in CHCl3. The solvent was evaporated
from the lipid solution using an ultrapure stream of nitrogen. The lipids were then
hydrated for 20 minutes (in a concentration of 2 mg/ml in Millipore water) at a
temperature above their highest transition temperature (100°C).
In the next step, the solution was sonicated 5 times for periods of 2
minutes (to form small unilamellar vesicles evenly distributed in size) [102].
Finally, the vesicle solution was used to submerge the PEG grafted glass slides.
The temperature was kept in the 90°C range, which was gradually lowered to
allow vesicles to diffuse onto the PEG cushion layer.

6.3.2.2. Self-Assembled Soft-Supported Lipid Bilayer Characterization
In the preparation of self-assembled membranes using vesicles, the first
step into characterization is the analysis of the vesicles size. Using the dynamic
light scattering (DLS) technique and instrument (Zetasizer Nano-S, Malvern, PA).
The second characterization step is the study of the surface topography of
the bilayer, and as explained for membranes deposited with LB, this surface
characterization is to be done with atomic force microscopy. However, because
the technique to provide the lipid bilayers using vesicles is still under
investigation, only the characterization of the vesicles size was performed.
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The results showed high instability in the formation of self-assembled lipid
bilayers. The sizes of the vesicles obtained, were highly variably in dimensions
(as shown in Table 8), and they were between 485 nm and 2348 nm.

Table 8. Dynamic Light Scattering. Results giving the sizes
of the multilamellar vesicles formed
Peak

Particle’s Diameter (nm)

1

2347.5 ± 401.9

2

484.8 ± 189.3

The presence of large vesicles is an inconvenience in the formation of the
lipid bilayer with this method (the optimum size should be between 40 nm to 100
nm). The lipid used in this study (DSPE), has a long hydrophobic tail, which
determines first, the creation of rather stables and large vesicles. Second,
causes a high transition temperature (100°C). This high transition temperature is
similar to the one required for PEG surface grafting, which could be altering this
last process. These reasons might explain the adverse results obtained for this
particular lipid.
In order to overcome the inconvenience in this technique, further testing
should be accomplished using short hydrophobic tail lipids with low molecular
weights, such as the following: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine
(DPPC), Sphingomyelin (SM. Ceramide-1-Phosphocholine. Brain, Porcine), and
1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC); all with MW between 730136

790. Additionally, cholesterol (Ovine wool, MW 387) can also be used in
combination with these lipids to attain the same effect.

6.4.

Chapter Remarks
In this study, a fluid cell membrane in vitro model was constructed to

present a brain-like environment approach [103] with the purpose of providing a
platform for future A! aggregation studies.
In the first stage of this proposed project, lipid (DSPE) bilayers were formed
on polyethylene glycol cushion support (PEG) using the Langmuir-Blodgett (LB)
deposition technique [104, 105]. The PEG layer was successfully used as a
stabilizer for the bilayers. It was observed that the PEG cushion layer offered
high mobility to the lipid bilayer membrane (Figure 68). Also, the PEG layer was
used to support self-assembled lipid bilayers formed from small unilamellar
vesicles, an alternative technique to prepared lipid bilayers.
Two important characteristics make this model a potential good platform
for in vitro A! aggregation studies: First, the high fluidity provided by the cushion
PEG layer underneath the lipid bilayer [105] gives the system fluidity that better
represents that of cell membranes in mammalian cells. Second, protein exclusion
characteristic of PEG also prevents proteins such as A! from breaching the lipid
bilayer and adsorbing directly on the substrate; this property makes this platform
also ideal for studies involving antibody-peptide interactions by confining these to
the surface of the lipid bilayer.
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CHAPTER 7
CONCLUSIONS

Alzheimer disease (AD) represents the main leading cause of dementia
typically among individuals over the age of 65. As life expectancy increases (76
year in 2006), also does the number of AD cases increases. As of today the
number of AD cases worldwide is approximately 26 million of individual affected
by the disease; and this number is estimated to increase to 106 million of cases
by the year 2050.
AD is known to affect the cognitive function, alter the social behavior and
body motor skills, among other affections related to the nervous system.
Nowadays, the causes of Alzheimer disease and onset mechanisms are yet
unclear. There are still pieces missing in the puzzle to fully understand the
disease and discern effective therapies to avoid and eradicate AD.
From the pathology of the disease, are known three hallmarks commonly
found in patients with AD, the extracellular formation of amyloid beta (Aß)
plaques, the presence of intracellular neurofibrillary tangles, and finally the
neuronal death. The hypothesis that gathers these hallmarks (amyloid
hypothesis) to explain the possible mechanism states that imbalance on the
catabolic process of Aß peptide leads to its accumulation forming neuronal
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plaques that trigger the formation of intracellular neurofibrlillary tangles and finally
terminate the neurons [51, 88, 89].
This work was studies and characterizes the mechanisms involved in the
process of Aß plaque formation and its possible clearance by using an
immunotherapeutic approach.
Two isoforms of the amyloid beta peptide were investigated separately
and combined in an equimolar mixture. These were, Aß1-40, and Aß1-42 peptides.
These two Aß isoforms are the main component of the neuritic Aß deposits (Aß
plaques) found in the brain of patients with AD.
In order to understand the process of aggregation, initial attention was
rendered to the study and characterization of the different species involved in the
aggregation process. When many species might be found during the process of
aggregation, for the effects of this study the species were classified as
monomeric, oligomeric, and fibrillar.
It is relevant to mention that amyloid beta owes its name to the
characteristic of its native secondary structure composition, which is mainly the
ß-structure type. ß-structures or more commonly known as ß-sheet structures
are structures composed by lateral connecting ß-strand structures, through 5 or
more hydrogen bonds. ß-strands are extended parts of the peptide formed by 5
to 10 amino acids.
The ß-sheet structures can be either parallel or antiparallel, depending on
the orientation of the strands forming the ß-sheet structures.
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Understanding these molecular configurations was important to interpret
the results obtained with ATR-FTIR spectroscopy; since, this technique allows
monitoring the secondary structures change by detecting the interactions
occurring through hydrogen bonding within and between the peptide molecules.
There are different points of view and disagreements on which is the most
energetically stable ß-strands configuration (parallel or antiparallel). However, the
results in this work showed that the stability of these structural configurations
highly depends on the peptide isoform under study. For instance, it was
observed that when Aß1-40 fibril were forming the dominant structural
configuration (in percentage) present along the process was the antiparallel type,
in addition to "-helix structures while parallel structures were reduced
considerably. In contrast, in the case of Aß1-42 peptide fibrillization, the structural
configuration of the parallel type seems to dominate the aggregation.
When oligomeric species are formed the configuration of the strand
structures also varied in accordance with the peptide, as for Aß1-40 oligomeric
species, the dominating arrangement was the parallel type, flipping to antiparallel
when the peptides are set to form fibrils, and as for the Aß1-42 oligomeric species
the antiparallel arrangement seems to dominate (and a-helix) flipping to parallel
configuration or rearrangement type.
Results in this study also suggested that the combination of the two
peptide isoforms shows competition between the secondary structures making
the fibrils morphologically different (thicker) from the peptides alone.
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This work included the addition of monoclonal antibodies (mAb) with
specificity to Aß with the purpose to modify or reverse the fibrillization process.
All experiments were carried out at close to physiological conditions (37°C and
pH 7.4). The antibodies used were chosen for their particular specificity to Aß
peptides and some for their potential use in therapeutic settings. These
antibodies were 6E10 (binds the N-terminus of both peptide isoforms), 2H6
(preferentially binds to the C-terminus of Aß1-40), 4G8 (binds the mid domain
either isoform), and a control antibody mIgG2b that has no specificity for either
Aß peptide.
Preformed fibrils targeted with antibodies 6E10 and 2H6 suffer secondary
structural change but not in a degree that allow fibril dissolution. The initial state
of aggregation resulted a convenient phase for the addition of antibodies. This is
evidenced by experiments in which the target point for antibody addition where
monomeric and oligomeric species. This resulted in antibody binding and
altering the fibrillization process (Chapter 6). This phenomenon was observed
when in two cases under equal incubation conditions but varying the species
targeted by the antibody. Preformed fibrils in solution were not easily dissolved,
but targeting monomer + oligomers in solution (at the initial fibrillization phase)
resulted in an evident effect of the antibody causing the disruption of the
fibrillization process.
This study points to the structural configuration of the ß-strands forming
the ß-sheet structures as the key to understand and explain at the molecular
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level the effects caused by antibodies to the different species of the peptides
isoforms studied in this work.
The combination of the analytical techniques (ATR-FTIR, AFM, TEM)
allowed the testing and evaluation of the peptide characteristics during
aggregation and allowed to explain the effects of antibodies observed when
targeting the different species of the Aß peptides.
Finally, it was possible to prepare a soft substrate mimicking the cell
membrane’s surface (Chapter 7), laying the groundwork for future experiments.
A polymeric film (PEG) grafted to SiO2 served as a cushion layer for the
deposition of a double layer of lipids. Langmuir-Blodgett resulted as the
preferential deposition technique due to the control on monolayer uniformity
before and during the lipids deposition. In the future, this membrane could be
optimized by inserting other cell membrane molecules; such as cholesterol, other
lipids, sugar groups, or proteins. This interface could potentially serve to test the
surface role on the process of plaque formation as function of rigidity, for
instance varying the amount of cholesterol inserted in the bilayer membrane.
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CHAPTER 8
FUTURE DIRECTIONS

The studies presented in this work leave a door open for new possible
paths to investigate, as described below.
• Measurement of surface energy of Aß peptide species, in particular
oligomers and protofibrils, which are the intermediate species in the
process of fibrillization, this can be performed with surface force
apparatus (SFA).
• The effects observed in the ATR-FTIR spectroscopic analysis can be
used to investigate synthetic analogs to antibodies that act on Aß
peptides. ATR-FTIR information can be utilized to detect secondary
structure fingerprints in molecule screening processes.
• Other amylogenic processes such as the hyperphosphorylation of Tau
protein (other hallmark of AD) can be studied using the methods
presented in this dissertation.
• Complementary techniques could be used to study binding and rate of
aggregation and dissolution to complement the ATR-FTIR such as
quartz crystal microbalance (QCM).
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• It is suitable to introduce polarized light to the ATR-FTIR spectrometer
to produce more complete information in regards to the structural
orientation of the molecules.
• Lipid bilayer membrane construction by self-assembled vesicles can be
improved by introducing a mixture of lipids with different tail lengths,
which might allow a controlled system at lower temperatures more
suitable for the preparation of these membranes.
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Appendix A. Isoelectric Points of Aß Peptides

Figure 69. Titration Curve of Aß1-40 Indicating its Isoelectric Point. Obtained from
http://biophysics.cs.vt.edu/H++/ (Virginia Tech) using the Protein Data Bank for
the peptide sequence.

Figure 70. Titration Curve of Aß1-42 Indicating its Isoelectric Point. Obtained from
http://biophysics.cs.vt.edu/H++/ (Virginia Tech) using the Protein Data Bank for
the peptide sequence.
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Appendix B. ATR Crystals
Table 9. Limitations and General Specifications of ATR Crystals
LWL
dp
Swater
pH
Hardness
Material
n1 [cm-1] [#m] [g/100g] Range [Kg/mm2]
AMTIR 2.5
625
1.46 Insoluble
1-9
170
Diamond/ZnSe 2.4
525
1.66 Insoluble 1-14
5,700
Diamond/KRS5 2.4
250
1.66 Insoluble 1-14
5,700
Germanium 4.0
780
0.65 Insoluble 1-14
550
KRS-5 2.4
250
1.73
0.05
5-8
40
Silicon 3.4 1500
0.84 Insoluble 1-12
1150
Silicon/Znse 3.4
525
0.84 Insoluble 1-12
1150
ZnS 2.2
850
2.35 Insoluble
5-9
240
ZnSe 2.4
525
1.66 Insoluble
5-9
120
n1 = refractive index of ATR crystal, LWL = long wave length cut-off, dp = depth
of penetration at 1000 cm-1, Swater = Solubility in Water
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